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Abstract
For industrial recombinant-protein processes, protein refolding and purification are crucial
steps towards the recovery of considerable numbers of active and safe therapeutic products.
In this thesis, intensification strategies for protein refolding and purification processes are
explored. Development of an intensified process aims at simultaneous optimization of
process performance indicators, namely: refolding yield, product purity, volumetric
productivity and solvent consumption which in turn decrease the cost and time constraints to
market.
The first strategy investigated related to multivariable experimental work using size
exclusion chromatography (SEC) as a refolding method and a denatured/reduced model
protein (lysozyme). SEC was selected due to its potential for refolding of higher
concentrations of protein compared to conventional refolding methods used currently in
industry. The investigated variables were protein loading concentration, refolding buffer
composition including pH, sodium chloride salt and ʟ-arginine, aggregation prevention
additive, concentrations. The interplay of these process variables was studied and it was
shown when ʟ-arginine is used, over the experimental space, the effects of pH and protein
loading concentration on refolding yield are insignificant. This observation introduced the
possibility of manipulating pH in a wider range without concerns for protein aggregation; for
instance, to adjust the redox potential of the buffer without the need for costly redox couple
chemicals to assist reformation of disulfide bridges in oxidative refolding of the protein. The
results also provide more experimental evidence on the mechanism of aggregation prevention
by ʟ-arginine. Secondly an experimentally-verified model of oxidative protein refolding on
SEC was developed, with the goal of high-throughput process screening and optimization
using the aforementioned model. Model development involved exploration of methods to
find characteristic information on short-lived refolding kinetic species and lysozyme
oxidative refolding kinetic schemes and constants under the two studied refolding
environments, namely with and without ʟ-arginine additive. It was shown that ʟ-arginine
prevents aggregation without considerable impact on the kinetics of lysozyme oxidative
refolding.
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Finally, SEC in a multi-column continuous simulated moving bed configuration (SMB-SEC)
was evaluated to fully exploit the potential of SEC for intensified protein refolding and
purification. This configuration offers several advantages compared to single-column
operation, including increased productivity per unit mass of solid phase, lower solvent
consumption, and less diluted products, provided that operation parameters are screened and
tuned for simultaneous optimization of process performance indicators. In this phase of the
project, the effect of scale-up was predicted and considered for modifying and utilizing
single-column model towards design/operation of a SMB-SEC. This thesis presents a
framework for protein refolding and purification process development and optimization,
including reduced cost of chemicals, improving the refolding yield, high-throughput
measurements of parameters and finding a suitable reaction scheme of refolding and
aggregation for mathematical model development applicable to both single-column and
multi-column continuous operations, and defining appropriate process performance
indicators for optimized operation of SMB-SEC.

Keywords
Inclusion-body-based protein; Intensified oxidative protein refolding; Mathematical
modeling; Multi-column continuous simulated moving bed.
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Chapter 1

1

1 Introduction
1.1 Recombinant-protein Technology
The advent of recombinant DNA-technology in the 1970s opened the possibility of
engineering and expressing valuable protein/peptide products using a host cell.
Recombinant human insulin and growth hormone were first introduced to the market in
the early 1980s improving the availability, quality and safety aspects of these products
which before were only available by tissue extraction from plants and animals [1]. The
market for recombinant bio-pharmaceuticals has been growing rapidly standing at 30
products with an estimated market value of 50 to 60 billion USD in 2004 [2] and reaching
to more than 151 unique products approved by the Food and Drug Administration (FDA)
and/or European Medicines Agencies for different clinical indications by 2012 [3].
Manufacturing of the biopharmaceuticals, including the above mentioned products,
involves drug discovery, expression of the desired product in the host cell (upstream),
cell line production (midstream), recovery and purification of active and pure product
(downstream) and drug formulation. These stages are integrated and it is important that
all phases of process development be designed in tandem for instance, screening the drug
candidates considering both efficacy and downstream processing requirements.
Otherwise, downstream operations can account for over 70% of the production cost as
they are greatly impacted by the presence of impurities and contaminants [4].
For recombinant-protein production, selection of host cells includes prokaryotes, yeast,
filamentous fungi, insect and mammalian cells. About 30% of the recombinant-proteintherapeutics are expressed in Escherichia coli (E.coli) due to its well-characterized
genetics, rapid growth and high level of expression, and low cost media; the level of
expressed product can reach up to 50% of the cell mass [1,3]. However, when E.coli is
used to express a protein of interest, due to over-expression and lack of necessary
condition (e.g. saturation of cell folding machinery), the protein molecules may not fold
to their unique three-dimensional structure known as native functional conformation. The
expressed unfolded/partially folded polypeptide chains are prone to intramolecular
2

interactions and aggregation. Particularly, when the expressed polypeptide chains contain
cysteine residues, formation of intramolecular disulfide bridges under over-expressed
condition promotes aggregation inside the cell [3,5]. These aggregates are called
inclusion-bodies (IBs); they are insoluble and contain large amount of inactive protein.
Table 1-1 shows some examples of therapeutics produced as IBs [1].
Table 1-1. Examples of IBs produced using recombinant DNA technology
Molecule

Companies

Indication

rh Insulin and analogs

Eli Lilly, Aventis

Diabetes treatment

Interferon alfacon-1

Valeant

Anti-viral

r Interferon β-1b

Schering AG, Chiron Anti-tumor

r Interferon γ-1b

Genentec

Anti-inflammatory

Intermune
rh IL-1 receptor -antagonist

Amgen

Immunotherapeutic-

r IL-2

Chiron

r IL-2-diphtheria toxin fusion

Seragen / Ligand

r IL-11

Genetics Institute

r Human growth hormone (r

Genentech, Eli Lilly,

growth hormone

hGH)

Pfizer, Schwartz-

deficiency

agents

Pharma, Novo
Nordisk

3

1.2 Downstream Processing of Inclusion-body-based Protein
Figure 1-1 illustrates the common route for downstream processing of IBs. After cell
harvest and disruption, IBs are easily separated from the impurities in the cell broth as
they are usually heavier than other cell components resulting in low level of impurities
(70-90% of total protein is often present in IBs) [3,5]. The separated IBs are commonly
further processed by addition of chaotropic reagents (i.e. denaturing and reducing agents
such as urea and DTT) or adjusting the pH of the buffer (pH induced solubilization) to
break the intra-molecular bonds and dissolve aggregates. The latter method of
solubilization is considered more economical but its applicability is limited and depends
on the nature of the aggregates as not all IBs are dissolved by adjusting the pH [6]. Once
aggregates are dissolved and unfolded protein monomer is obtained further downstream
processing aims at recovering the protein monomer in its folded functional conformation
(protein refolding) and eliminating remaining contaminates from the host cell if they are
not separated during IB recovery as well as soluble aggregate impurities that might be
formed during the process. Similar to in-vivo refolding of unfolded/partially folded
polypeptide chains, the in-vitro refolding is also susceptible to aggregation and
misfolding. In other word, the correct folding pathway competes with aggregation and
misfolding. Separation of soluble aggregates is crucial as they can cause unwanted
autoimmune responses [7–9]. These species are also linked to neurodegenerative diseases
such as Alzheimer and Parkinson; ongoing research suggest that protein aggregation
formation may be a symptom of the disease rather than cause of the disease [10].
Accordingly, if aggregates cannot be reduced to an acceptable level below the World
Health Organization limits, a protein with therapeutic potential may be dropped from
development.

4

Bioreactor

Cell harvest &
disruption

Removal of cell
debris

IBs wash

IBs solubilization

Protein refolding&
purification

Figure 1-1. Downstream processing of inclusion bodies (IBs)

1.2.1 Protein Refolding Methods
Refolding strategies have involved two main categories to date, namely dilution and
separation. In both cases reduced local concentration of denaturing and reducing agents
surrounding unfolded protein molecule promotes formation of folded conformation.
Batch dilution is considered the easiest method and used in industrial operation; however,
the working concentrations are low to avoid aggregation formation which in turn results
in higher buffer consumption, low volumetric productivity, handling large volumes and
additional concentration steps [6]. Various matrix assisted chromatography (MAC)
methods such as ion-exchange, hydrophobic, affinity and size exclusion chromatography
(SEC), have been used at lab scale as separation methods [11–14]. MAC methods allow
for higher protein concentrations to avoid aggregation due to spatial isolation of unfolded
molecules while adsorbed on the matrix surface or gradual separation of chaotropic
reagents from unfolded protein molecules. Although MAC techniques are also
accompanied by dilution, considering the lower dilution factor and higher loading
concentrations compared to dilution method, they result in more concentrated product. In
5

addition, the possibility of separation of impurities within the same unit holds a promise
to eliminate the need for further processing to meet the standards in terms of impurity
levels. Among different matrix assisted methods, SEC is a non-adsorptive technique and
separation is achieved by different migration velocities according to the size of the
species. The negligible interaction with the matrix may be advantageous compared to
adsorptive methods. For instance, ion exchange chromatography may result in low
recovery [15] unless multiple gradient schemes in terms of buffer pH, urea and salt
concentrations are used [16]. Depending on properties of the adsorptive surface and
protein, protein might remain unfolded and tend to aggregate while adsorbed on the
surface. In these cases the highest productivity is achieved by low contact time with
matrix and off-column refolding [17,18]. In contrast to hydrophobic chromatography,
protein refolding on SEC requires refolding buffer containing low concentration of salt to
prevent non-specific interactions [19], while high salt concentration requirement for
protein binding in hydrophobic chromatography may be problematic when working with
unfolded protein due to reduced solubility of these species compared to native
conformation [5,20]. For these reasons, SEC has been considered for potential intensified
protein refolding and purification and has been used at lab scale both in the form of batch
single-column processing and multi-column continuous simulated moving bed operation
(SMB-SEC) [6,19,21–27].

1.2.2 Fundamentals of Protein Folding/Refolding
In 1972 Christian B. Anfinsen (1972 Chemistry Nobel Prize) showed that native proteins
can be unfolded using denaturing condition (e.g. breakage of disulfide bridges) but this
unimolecular reaction can be reversible and native conformation of the protein is
recovered under non-denaturing conditions [28]. Anfinsen’s work resulted in the
assumption that the native state is thermodynamically the most stable conformation under
suitable conditions. However, this general acceptance was challenged by experimental
protein aggregation studies. Baldwin et al. [29] observed that regardless of the sequence
of the protein, when protein concentration surpassed a critical solubility concentration
they aggregate to form amyloid fibril, a structure rich in β-sheet content, indicating that
amyloid fibril is the most stable conformation . In the same work the cellular
6

concentration of the proteins under the study were compared to their equilibrium
concentration and found to be higher than equilibrium concentrations. The question
raised in this work is: how proteins have evolved to avoid aggregation during their
normal life span in-vivo? One suggestion is that the native protein in cell is metastable
compared to amyloid fibril and there is a large kinetic barrier between folded functional
and

aggregate

states.

Consequently,

protein

stability

is

controlled

both

thermodynamically and kinetically [29,30] yet there is no clear understanding that what
causes kinetic stability of the protein inside the cell [31]. The overall stability of the
native protein is the result of enthalpic (e.g. ionic bonds, hydrogen bonds and Van der
Waals forces) and entropic contributions (release of disordered water molecules due to
hydrophobic effect) that balance the large conformational entropy penalty associated with
folding [32]. The native state is usually not much more stable than unfolded state and
slight changes of the above mentioned interactions can induce unfolding such as
temperature variation and chemical composition of the solvent.
Protein folding/refolding pathway has been classified to two main categories namely
cooperative and non-cooperative. The former involves only two states (unfolded and
folded) whereas the latter involves at least one intermediate state. Many proteins,
especially small single domain species with less than 100 amino acids, fold in a two-state
fashion [33]. However, larger proteins tend to deviate from two-state behavior. For
example, the refolding of the model protein used in this work (lysozyme composed of
129 amino acids) involves a “collapse process” and at least one kinetic intermediate.
There have been controversial approaches in describing collapse process (burst phase)
[34]. The question is whether this phase represents a folding/refolding step or is a
reflection of sudden change in the solvent properties and involves non-specific
interactions. The latter description is supported by experimental evidence on observation
of burst phase for proteins that cannot fold [35] whereas some research work debate
specific nature of collapsed conformation (i.e. early intermediates) [36]. Further details
regarding mechanism of lysozyme refolding and aggregation is provided in sections 3.2.2
and 4.2.3.
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1.3 Research Contributions
Despite extensive experimental work and successful utilization of SEC at lab scale for
protein refolding and purification, there is still work to be done to consider feasibility for
industrial application of this technology. Major contributions of this work to the research
field are outlined here and found in chapters 2, 3 and 4 of this thesis in more details.
Chapter 2: Multi-variable Operational Characteristic Studies of On-column
Oxidative Protein Refolding at High Loading Concentrations [37]
The first contribution from this thesis relates to quantifying the interaction of ʟ-arginine
additive with refolding buffer pH and model protein loading concentration (lysozyme). A
synthetic feed (denatured/reduced lysozyme obtained by addition of denaturing and
reducing agents to naturally occurring lysozyme) was used throughout this work. The
rationale for this approach was that regardless of the source of the protein (naturally
occurring or recombinant), the refolding task involves dilution/separation of denaturing
and reducing reagents from unfolded protein monomer. Lysozyme has been extensively
studied as a model system for oxidative refolding due to importance of disulfide bond
formation in considerable number of proteins.
It was shown that the effect of both pH and protein concentrations on the refolding yield
in the presence of low concentrations of ʟ-arginine (0.2 M) are trivial. In addition, in the
presence of this additive and high protein loading concentrations (40 mg/mL) pore
accessibility was reduced. Observations made in this study provided more experimental
evidence towards the suggested mechanism of protein aggregation suppression by ʟarginine and introduced the possibility of manipulating pH for adjusting the reducing
potential of the buffer in oxidative refolding of the proteins, thereby potentially
eliminating the need for an expensive redox couple commonly used in refolding
practices.
Chapter 3: Oxidative Protein Refolding on Size Exclusion Chromatography at High
Loading Concentrations: Fundamental Studies and Mathematical Modeling [38].
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The second contribution is the development of an experimentally-verified mathematical
model of oxidative protein refolding on SEC for fast screening of process parameters. A
detailed kinetic scheme was investigated and various methods including quenched and
equilibrium experiments as well as application of model compounds were introduced to
obtain characteristic information on refolding kinetic species. It was demonstrated that
characteristic information obtained from experiments on SEC may be erroneous due to
non-specific interaction of species with the matrix. Kinetic studies showed an apparent
two-state kinetic scheme including early intermediates and the native protein is
significantly more accurate compared to commonly simplified mechanism including
native-like intermediate to native protein. In addition under two explored chemical
environments, namely with and without ʟ-arginine, the mass transfer characteristic and
kinetic studies showed that low concentration of ʟ-arginine (0.2 M) increases the
refolding yield of lysozyme with no considerable impact on the kinetics but did effect the
mass transfer characteristics of lysozyme in SEC.
Chapter 4: Oxidative protein refolding on size exclusion chromatography: From batch
single-column to multi-column counter-current continuous processing.
The third contribution from this thesis comes from introducing modifications into the
model developed in the previous chapter in order to expand its applicability for prediction
of protein behavior through columns connected in series in a SMB-SEC as a scale-up
method. Aggregation was incorporated into the model to consider for higher local protein
concentrations in SMB-SEC, due to the lower dilution factor in this system compared to
the single-column operation. It was demonstrated that in a wide working concentration
range the refolding/aggregation is best described as occurring when local protein
concentration is equal or higher than a critical concentration (i.e. solubility of early
intermediates), which can be measured. Examining the local denaturant concentration
through the SMB-SEC confirmed the findings of previous research work that a model
with constant kinetic and thermodynamic parameters may not provide an accurate
estimate of early intermediate to native protein ratio at the product outlet. It was also
shown that an unfolding reaction should be added to consider the higher local
concentration of denaturant which occurs due to lower dilution factor compared to single
9

column. Based on predictions of the denaturant concentration at the product outlet it was
concluded that the refolding reaction will continue off-column. Accordingly, process
performance indicators were defined based on solubilized protein (early intermediates
and functional native protein) which does not require differentiating between the
solubilized conformations. This work demonstrated that a model with constant
parameters is suitable for screening the operation parameters and optimization of the
performance of a SMB-SEC unit if these effects are taken into account.
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2 Multi-variable Operational Characteristic Studies of On-column
Oxidative Protein Refolding at High Loading Concentrations
Abstract
Chromatographic-based protein refolding techniques have proven to be superior to
conventional dilution refolding methods, due to the higher loading concentration and
simultaneous purification. Among these techniques, Size Exclusion Chromatography
(SEC) has in particular been demonstrated as an effective method for refolding of variety
of proteins. To date existing studies of protein refolding at high concentrations (>1
mg/mL) in SEC have primarily been conducted as single factor studies, in which a single
parameter is varied to assess impact on operating performance, which does not allow for
determination of the interactions of different operating parameters and optimized
operating conditions. In this work a multi-variable investigation of size exclusion protein
refolding at high protein concentration using lysozyme as a model protein was
performed, in order to quantify the interaction of factors and optimize performance. It
was observed when ʟ- arginine is used as an additive the refolding yield becomes
independent of the protein concentration and refolding buffer pH, providing that a redox
couple is used to assist the reformation of disulfide bridges. Furthermore, the pore
accessibility for small molecules was reduced in the presence of this additive particularly
at higher protein concentrations indicating slower removal of these molecules and a
possible additional mechanism of aggregation prevention. Using the subsequent
optimized refolding buffer, a refolding yield of more than 90% was obtained for up to 40
mg/mL loading concentration of lysozyme which has only been reported for a urea
gradient SEC (8-2 M) with lower equilibration and elution flow rates due to high
viscosity of buffer containing high concentrations of urea.

2.1 Introduction
Proteins are one of the most important biological compounds and beneficial to human
health when used as therapeutic agents. Recombinant DNA technology continues to be
one of the common methods in industry for production of many biopharmaceuticals,
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including proteins [1]. In particular, Escherichia coli (E. coli) is one of the most used
microbial expression systems in biotechnology due to its well characterized genetics,
very high expression level and ease of manipulation [2]. One of the primary issues
resulting from protein expression in E. coli is the formation of inactive protein aggregates
(inclusion bodies). These aggregates require solubilisation through providing an
environment for protein chains to unfold, which may be accomplished by using
denaturing and reducing agents. After unfolding and aggregate collapse, the refolding of
proteins into their compact structures is critical in order to restore biological activity and
functionality. Refolding by dilution is commonly practiced in laboratories and industry
due to its simplicity in design and operation [3–5]. However the correct protein folding
pathway often competes with misfolding and aggregation, particularly at high
concentrations which substantially reduces refolding yield. Furthermore, the presence of
aggregates in the final product as impurities provides health concerns for utilization as
therapeutics [6]. Consequently, the dilution technique has serious drawbacks during
scale-up due to requiring low product concentrations and purity in addition to large
process volumes, which necessitate additional cost-intensive post-refolding concentration
and purification steps. These challenges limit high throughput production of therapeutic
proteins and the speed with which new protein drugs can be brought to market [3].
Recently, chromatographic based refolding [3,7–9] has drawn great attention to address
the challenges associated with product dilution, by facilitating spatial isolation of protein
molecules and unfolding agents based on different affinity for solid phase or molecular
size. These methods allow for protein refolding at higher concentrations and
simultaneous protein purification due to reduced intramolecular interactions in adsorptive
chromatography methods and gradual separation of protein and unfolding agents waves
in

non-adsorptive

size

exclusion

chromatography

(SEC).

Among

various

chromatographic methods, SEC offers many advantages and has been widely used at lab
scale for protein refolding in either batch or continuous mode [3,10–15]. The
performance of SEC in terms of refolding yield, protein recovery and purity depends on
many parameters, such as: protein structure, protein concentration, loading state of nonnative protein (e.g. denatured, denatured and reduced), column packing specifications
(e.g. material, particle size, pore size), refolding buffer composition including its pH,
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redox potential, ionic strength and additives’ concentrations [14–19]. However, the
majority of research related to operational characteristics of SEC refolding pursued onefactor-at-a-time approach which cannot quantify the interactions of factors preventing
determination of optimal operating conditions. In this work, a multi-variable study of key
parameters on SEC refolding at high concentrations was carried out, using lysozyme as a
model protein.

2.2 Design of Experiments
A suitable refolding buffer is particularly critical in refolding of proteins. The refolding
buffer reported to give highest refolding yield for lysozyme is comprised of 0.1 M Tris, 1
mM EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cystine or the same concentration of
glutathione redox couple buffered at pH 8.1 [15]. In this work, the reported refolding
buffer (0.1 M Tris, 1 mM EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cysteine buffered at
pH 8.1) was initially used to identify protein concentrations at which aggregates are
formed. This is followed by a buffer optimization process to minimize the aggregation
and increase the refolding yield. ʟ- arginine is commonly used to increase the protein
mass recovery in various liquid chromatography columns [20,21] and has been proven to
be an effective aggregation suppressor due to its unique effects on protein association and
folding [22–26]. Higher concentrations of ʟ- arginine results in higher refolding yields,
but it also slows down the rate of refolding [24,25]. Therefore, the concentration of ʟarginine was selected as one of the key factors which affect the refolding yield of
lysozyme by SEC. Apart from ʟ- arginine concentration, refolding buffer pH, ionic
strength and protein concentration are the other key factors which dictate the refolding
yield of lysozyme [14,15,17,19]. A two-level full factorial design of experiment
combined with replicated center point runs to test for curvature was executed in the
current work to investigate the effect of the aforementioned operating parameters and the
potential interactions between these factors. An empirical equation was developed to
predict the refolding yield in the experimental space and search for optimum within the
design space.
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2.3 Materials and Methods
2.3.1 Chemicals
Reagent grade ʟ- arginine and urea, Ethylene Diamine Tetra Acetic acid (EDTA),
lysozyme from chicken egg white, trizma® base (Tris-base), ʟ- cysteine, ʟ- cystine, BioUltra dithiothreitol (DTT) solution, Micrococcus lysodeikticus, potassium phosphate
monobasic and BioXtra sodium chloride were purchased from Sigma-Aldrich, Canada.
Red660™

protein

assay reagent

was

purchased

from

G-Biosciences,

USA.

Superdex™75pg resin (24-44 µm) was purchased from GE healthcare, Canada.

2.3.2 Feed Preparation
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1)
was used to prepare various concentrations of denatured and reduced lysozyme. The
sample was incubated for 2-4 h at 37 °C to ensure loss of activity which was confirmed
by enzymatic activity test as described below [15].

2.3.3 Refolding by Size Exclusion Column
XK16/40 column (GE healthcare, Canada) was packed with Superdex™75pg resin. The
total volume of column was 44mL and the packing quality was tested by comparing the
peak symmetry and number of theoretical plates per length of column with manufacturer
recommended criteria using 2% (v/v) acetone injection. The packed column was installed
on ÄKTA purifier 100, controlled by UNICORN 5.31 software equipped with online pH
probe, UV detector and conductivity cell. The fractionation kit allows the collection of
samples at desired volumes. The column was equilibrated with 2 column volumes (CV)
of refolding buffer prior to protein injection. After equilibration, 0.5 mL of denatured and
reduced lysozyme was injected and eluted for 1.5 CV with refolding buffer at 1 mL/min
flow rate. During elution fractions of 7 mL were collected and stored at 4 °C before
analysis which was conducted in less than 24 h. The stability of samples during storage
was tested by comparing the enzymatic activity of samples analysed immediately and
stored ones which showed no significant difference [27]. The fractions were pooled to
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measure total protein recovery (𝑅𝑏 %), refolding yield (𝑌%) and purity (𝑃𝑏 %) as defined
below.
𝑀𝑡𝑜𝑡𝑎𝑙
𝐿𝑉𝑖𝑛𝑗

(2-1)

𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝐿𝑉𝑖𝑛𝑗

(2-2)

𝑅𝑏 =

𝑌=

𝑚𝑜𝑛𝑜
𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝑃𝑏 = 𝑚𝑜𝑛𝑜
𝑀𝑡𝑜𝑡𝑎𝑙

(2-3)

where Mtotal and Mnative are total protein and equivalent native protein mass collected in
pooled fractions associated with either all forms of protein or protein monomer which
were measured by total protein and enzymatic activity assays as described in analytical
methods, Vinj is injection volume, L is lysozyme loading concentration.
The column was then washed with 2 CVs de-ionized water after elution. In case of incolumn protein precipitation and flow blockage, the column was washed with 6 M urea,
32 mM DTT, 0.1 M Tris-base buffered at pH 8.1 at very low flow rates (< 0.2 mL/min)
to dissolve the precipitated aggregates.
All the buffers were prepared fresh using ultra-pure water (Barnstead easy-pure RODI
equipped with 0.2 µm filter, Fisher Scientific), filtered again with a 0.2 µm membrane
and de-gassed prior to use.

2.3.4 Analytical Methods
2.3.4.1

UV Absorbance

The lysozyme powder was dissolved in 0.1 M potassium phosphate and 0.15 M NaCl
buffer (pH 7) and the lysozyme content was determined by ultraviolet (UV) absorption
spectroscopy (Shimadzu UV-3600) at 280 nm using extinction coefficient of 2.63
mL/mg/cm. The feed concentration (denatured and reduced lysozyme) was confirmed
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using extinction coefficient of 2.37 mL/mg/cm. Feed samples were diluted in 0.1 M
acetic acid [27].

2.3.4.2

Enzymatic Activity

In order to determine the concentration of equivalent native protein (activity recovery) in
pooled fractions, the enzymatic activity of samples were compared with enzymatic
activity of standard protein samples prepared in the same buffer as used for on-column
refolding. The enzymatic activity was measured by recording the linear decrease of cell
suspension absorbance (0.15 mg/mL Micrococcus Lysodeikticus in 0.1 M potassium
phosphate buffer, pH 7) at 450 nm for 40 s [15], with all measurements in triplicate.

2.3.4.3

Total Protein Concentration

The total protein concentrations in pooled fractions were determined using Red 660™
protein assay in which 50 µL protein samples was transferred to a test tube. 1 mL of
reagent was added and mixed. The absorbance of the mixture was measured at 660 nm
after 5 min. The total protein concentrations were calculated by comparing the sample
and standard absorbance.

2.4 Results and Discussions
2.4.1 SEC Refolding of Lysozyme
Figure 2-1 (A and B) illustrate the chromatograms of SEC refolding of lysozyme at
various protein concentrations (5-40 mg/mL) using refolding buffer of 0.1 M Tris, 1 mM
EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cystine. The fractions associated with
aggregates and protein monomer were pooled to measure total protein recovery and the
protein monomer fraction pool was used to measure purity and refolding yield as defined
earlier, with the results summarized in Table 2-1. As expected, increasing protein
concentration decreased the refolding yield due to the aggregation. However, under the
current operating conditions (e.g. gel pore size, elution flow rate, refolding buffer
composition), the aggregates are soluble and completely separated from protein monomer
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in SEC column based on size, with larger aggregate molecules eluting before monomers.
Therefore, close to 100% purity of protein monomer was attainable, highlighting the
advantage of SEC for simultaneous protein refolding and purification after refolding. The
last peak in all chromatograms corresponds to DTT, which due to low molecular weight
can penetrate deeper in the gel pores.

Figure 2-1. Chromatograms of SEC refolding of lysozyme (A) at low loading
concentrations, (B) at high loading concentrations. Peaks from left to right: aggregate(s),
protein monomer and DTT.
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Table 2-1. SEC operating conditions, total protein recovery (𝑅𝑏 %), refolding yield (𝑌%)
and purity (𝑃𝑏 %)
L (mg/ml) Minj (mg) Mtotal (mg) Mnative (mg) 𝑅𝑏 (%)

𝑃𝑏 (%)

𝑌 (%)

4.5

2.25

2.3

2.48

100

100

100

9.05

4.52

4.47

4.3

98

100

95

18.26

9.13

9.56

7.7

100

100

84

36.03

18.01

16.1

11.37

89

95

63

2.4.2 Multi-variable Studies of Refolding of Lysozyme at High
Concentration
A polynomial with linear and interaction terms was fit to measured experimental
conditions to correlate the refolding yield (Y%) to lysozyme protein concentration (L)
(20-40 mg/mL), refolding buffer pH (B) (8.1-9.5), NaCl salt (S) (0-0.2 M), ʟ- arginine
(A) (0-0.2 M) concentrations and their significant interactions. Table 2-2 reports the
model coefficients, along with 95% confidence interval.
The analysis of variance (ANOVA) of the developed empirical fit showed the overall
probability of 0.0001 which translates to 99.99% confidence that the coefficients are not
zero. The model terms have p-values smaller than 0.05 indicating their significance
within 95% confidence interval. Probability plots showed normal distribution of error
and, as shown in Figure 2-2, good agreement between predicted and experimental results
is achieved using this model for refolding yield >10%.
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Table 2-2. Estimated empirical fit parameters and their confidence interval
Parameter

Fit Coefficient

Relative Confidence- interval (%)

Intercept

54.55

7.06

L

-13.78

29.95

B

-10.53

39.59

S

-18.16

22.97

A

11.21

37.19

LS

-5.84

70.69

LA

5.78

71.38

BA

8.28

50.35

SA

-10.59

39.38
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Figure 2-2. Experimental and predicted SEC refolding yield. The predicted SEC
refolding yield was obtained using empirical fit.
The fit coefficients for individual parameters suggest that higher refolding yields are
attained at low protein concentration, salt concentrations, refolding buffer pH and high ʟarginine concentrations. However, as Figure 2-3 (A and B) shows when 0.2 M ʟ- arginine
is used as an additive in the refolding buffer protein concentration and refolding buffer
pH demonstrated insignificant effect on the refolding yield in the experimental range
tested in this work.
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Figure 2-3. 3D surfaces generated using empirical fit; (A) pH = 8.8, no salt, redox couple
(3 mM cysteine, 0.3 mM cystine) (B) Concentration = 30 mg/mL, no salt, redox couple
(3 mM cysteine, 0.3 mM cystine). Y: refolding yield, L: lysozyme concentration, B:
refolding buffer pH and A: L-arginine concentration.
High protein concentration can reduce the refolding yield due to increased intramolecular interactions and protein aggregation. The refolding buffer pH influences the
ionic interactions and redox potential of the system and is recognized as one of the most
influential parameters in protein refolding. For lysozyme refolding, working at pH 9.5
decreased the refolding yield compared to pH 8.1. Although negligible amount of
solubilized aggregates were formed at pH 9.5 (Figure 2-4), aggregation was observed
outside the column in the fractions associated with protein monomers. Working at pH
closer to protein isoelectric point (11.35) presumably reduces electrostatic repulsion and
protein solubility, which can result in the aggregation of unfolded, intermediate or native
species.
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Figure 2-4. Chromatograms of SEC refolding of lysozyme at 20 mg/mL loading
concentration and pH 9.5.
However, when ʟ- arginine is used, formation of protein-associated arginine clusters
“crowds out” the protein molecules and prevents self-association and aggregation
[22,23]. As shown in Figure 2-5 (A and B) no aggregates were formed independent of
lysozyme loading concentration and refolding buffer pH .It was hypothesized that the
overlapping peak eluting before refolded lysozyme is an ensemble of early kinetic
intermediates with only a fraction of correct disulfide bridges, little structure and buried
tryptophan residues [28]. Refolding without a redox couple results in the recovery of
species with similar characteristics by preventing rearrangement and formation of correct
disulfide bonds [29]. Therefore, the refolding was also conducted without redox couple to
gain more information on the species eluting before refolded protein. As Figure 2-5 (C)
illustrates, at pH 8.1 no refolded lysozyme was recovered when the redox couple was
removed and the eluting peak has the same retention volume as the first peak in the run
with the redox couple (Figure 2-5B). The enzymatic activity test of the protein pool also
confirmed no activity recovery. The higher redox potential at pH 9.5, allows for the
refolding to proceed even without redox couple and self-association is prevented due to
the presence of ʟ- arginine. However, the reaction is slightly slower and the first eluting
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peak is more populated. Nevertheless, its elution volume is identical to the experiment
with the redox couple (Figure 2-5B). In both cases early kinetic intermediates were stable
in the time scale of chromatography experiments and only partially precipitated outside
the column overnight during storage. This is of particular interest when information about
the size of kinetic intermediate is required for undertaking modelling and scale up.

Figure 2-5. Effect of L-arginine using refolding buffer pH 8.1 and 9.5. (A) loading
concentration of 20 mg/mL, (B) loading concentration of 40 mg/mL, and (C) loading
concentration of 40 mg/mL without redox couple. The reduced pore accessibility due to
presence of ʟ-arginine is evident from DTT elution volume.
Another interesting observation of this work was faster elution of small molecules of urea
and DTT when ʟ- arginine is added to the refolding buffer particularly at high protein
concentrations. DTT elutes at 48.7±0.5 mL when no arginine is used regardless of protein
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concentration (Figure 2-1A, B and Figure 2-4). However, its elution volume is influenced
by protein concentration in the presence of ʟ- arginine eluting at 47±0.2 mL and 43.4±0.2
mL for loading concentrations of 20 mg/mL and 40 mg/mL respectively (Figure 2-5A, B
and C). Forrer et al. [30] demonstrated that the accessible porosity of an ion-exchange
material is reduced at high protein concentrations, due to the increased protein binding to
the resin surfaces. For the current study in SEC column, reduced pore accessibility for
small molecules may be responsible for their faster elution due to formation of proteinassociated arginine clusters with larger sizes compared to protein monomer. The reduced
transport properties for denaturing and reducing molecules achieved by the application of
ʟ- arginine at high protein concentrations can prevent sudden removal of these molecules
and protein aggregation [15,17], another mechanism by which ʟ- arginine can affect the
on-column refolding yields at high concentrations.
Adding NaCl to refolding buffer led to in-column precipitation, and in some cases, flow
blockage. Flow blockage happened immediately after injection due to decreased
solubility of unfolded lysozyme which is no longer protected by urea molecules after
their immediate diffusion into the gel pores [18]. This is in contrast to lower loading
concentrations in which similar concentration of NaCl is used and recommended to
reduce the non-specific interactions in SEC columns [14]. As an alternative, optimized
concentration of ʟ- arginine can be used to reduce the non-specific interactions with the
gel and solid surfaces during purification and storage [21,31].
Using the subsequent optimized condition above 90% refolding yield was obtained for
concentration as high as 40 mg/mL. The highest reported activity recovery for high
concentration lysozyme (30.1 mg/mL) refolding in SEC is 80% [17] achieved by urea
gradient SEC in which linear decrease of urea concentration along the column (8 M to 2
M) prevents the aggregation. However, the challenge of column equilibration with a
buffer containing 8 M urea is high pressure drop due to high viscosity of the buffer.
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2.5 Conclusions
The multi-variable investigation of lysozyme refolding in SEC at high concentrations
carried out in this work revealed: (1) insignificant effect of protein concentration and
refolding buffer pH on refolding yield at the presence of ʟ- arginine provided suitable
redox couple is used; (2) reduced pore accessibility for small molecules of urea and DTT
in SEC at the presence of ʟ- arginine and high protein concentrations; (3) early kinetic
intermediates were identified during refolding with ʟ- arginine and found to be stable in
the time scale of experiments in this work which allowed for size measurements in SEC.
The possibility of working at high pH values for proteins with basic isoelectric points
without self-association and aggregation problem due to the presence of ʟ- arginine might
eliminate the need for addition of expensive redox couple. The reduced pore accessibility
for denaturing and reducing molecules is an important factor in SEC refolding of protein
as it prevents sudden removal of these agents and could be an additional mechanism by
which ʟ- arginine additive prevents aggregation at high protein concentrations. These
findings also provide more experimental evidence on proposed mechanism of arginine
and protein interactions.
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3 Oxidative Protein Refolding on Size Exclusion
Chromatography at High Loading Concentrations: Fundamental
Studies and Mathematical Modeling
Abstract
Size exclusion chromatography has been demonstrated as an effective method for
refolding a variety of proteins. However, to date process development mainly relies on
laboratory experimentation of individual factors. A robust model is essential for highthroughput process screening and optimization of systems to provide higher productivity
and refolding yield. In this work, a detailed kinetic scheme of oxidative refolding of a
model protein (lysozyme) has been investigated to predict the refolding results in SEC.
Non-reactive native, quenched and equilibrium studies were conducted to obtain the
model parameters for the species formed during refolding of denatured/reduced
lysozyme. The model was tested in various operating conditions, such as: protein loading
concentration, injection volume, flow rate and composition of refolding buffer with and
without the use of ʟ-arginine additive. An apparent two-state mechanism was found
adequate to describe refolding of lysozyme on SEC for the operating condition tested in
this work. Furthermore, using low concentration of ʟ-arginine combined with urea as
common aggregation suppressor additives showed insignificant change in kinetics of
refolding of lysozyme on SEC. However, addition of ʟ-arginine changed mass transfer
properties of some of the species formed in refolding reaction which was considered in
the model to accurately predict the result of refolding on SEC.

3.1 Introduction
The conventional method of protein refolding, namely batch dilution refolding, requires
working at low protein concentrations in order to prevent aggregation, which in turn
results in low productivity impeding high-throughput protein refolding and downstream
processing for production of many bacterially expressed recombinant proteins [1]. Size
Exclusion Chromatography (SEC)-based protein refolding addresses this issue to some
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extent by facilitating gradual spatial isolation of protein molecules and unfolding agents,
which can prevent aggregation and allow for application of higher protein loading
concentrations and simultaneous purification compared with batch dilution refolding. For
these reasons SEC has been widely used at lab scale for protein refolding in either batch
or continuous mode using single or multiple column configurations (i.e. simulated
moving bed) [1–9]. Existing work has also developed mathematical models for separation
in SEC using various model proteins in their native forms [10,11]. For protein refolding
in SEC (reaction-separation SEC), the refolding reaction is incorporated into the
mathematical model as well as interactions of aggregating species in case they are formed
under the operating conditions being studied and the model parameters must be obtained
for kinetic species formed during these reactions [5,12]. Development of an
experimentally verified and robust model helps minimize the number of screening
experiments for a broader range of operation condition and is essential for systematic
process optimization.
The mechanism of oxidative refolding reaction is commonly simplified to include only
one intermediate involved in the rate limiting step based on dilution oxidative refolding
kinetic data [13,14]. However, the ratio of kinetic constants of refolding steps is
influenced by chemical composition of the environment [13,14] and this simplification
may not be applicable in all cases. This is important in SEC as the refolding reaction is
accompanied with protein size variation and a correct scheme of such variation along the
column is necessary to accurately predict the elution profile of the protein. Furthermore,
in case of aggregate(s) formation, the simplified mechanism is not able to capture the
interactions of all intermediates that are prone to aggregation [5,14,15]. In this work, (1) a
mathematical model for refolding of denatured/reduced lysozyme in SEC at high loading
concentrations was developed to investigate a detailed reaction mechanism previously
proposed for this protein which was selected as a model system due to importance of
disulfide bond formation in considerable number of proteins [13]; (2) non-reactive native,
quenched and equilibrium experiments were executed to find the model parameters for
the final product and short-lived kinetic intermediates formed during unimolecular
refolding reaction; (3) the model was tested by varying operating conditions, namely:
protein loading concentration, injection volume, flow rate and composition of refolding
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buffer (with and without ʟ-arginine additive); and (4) the effect of low concentration (0.2
M) of ʟ-arginine on mass transfer and kinetic parameters in SEC was studied. ʟ-arginine
has been extensively studied and used to increase the refolding yield in batch dilution
refolding by suppressing aggregation [16–19] and protein mass recovery in
chromatography methods by decreasing non-specific interaction with the matrix [20,21].
In terms of kinetics of refolding, Reddy et al. [19] have reported insignificant change in
apparent kinetic constant of oxidative refolding of lysozyme by batch dilution using
guanidinium chloride and low concentration of ʟ-arginine (up to 0.5 M) to suppress
aggregation. However in contrast to this, Chen et al. [18] observed a considerable
decrease when both urea (2 M) and ʟ-arginine (0.5 M) were used in batch dilution
refolding of recombinant human granulocyte colony-stimulating factor. Furthermore,
Vagenende et al. [16] illustrated protein destabilization at the presence of low
concentration of ʟ-arginine (<0.5 M) by differential scanning calorimetric method which
might in turn result in reduced folding kinetics. To our knowledge there is no conclusive
information available on the effect of ʟ-arginine on mass transfer properties of various
refolding species and the kinetics of this reaction in SEC, making it a topic worthy of
investigation.

3.2 Modeling
The protein refolding in size exclusion column was modeled using the transportdispersive and solid-film linear driving force models formulated from differential mass
balances for solutes in the bulk-fluid phase and the particle-solid phase respectively [5].
The governing equations are
𝜕𝐶𝑏,𝑖
𝜕 2 𝐶𝑏,𝑖
𝜕𝐶𝑏,𝑖
= 𝐷𝐿
−𝑢
− 𝑃𝑘𝑜𝑣,𝑖 (𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖 ) + 𝑟𝑏,𝑖
2
𝜕𝑡
𝜕𝑥
𝜕𝑥

(3-1)

𝜕𝐶𝑠,𝑖
= 𝑘𝑜𝑣 (𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖 ) + 𝑟𝑠,𝑖
𝜕𝑡

(3-2)

where 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖 are the concentration of solute 𝑖 (unfolded, intermediates and native
conformations) in bulk-fluid phase and solid phase respectively. 𝑡 is time, 𝑥 axial
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distance along the column, 𝐷𝐿 axial dispersion coefficient, 𝑢 interstitial velocity, 𝑘𝑜𝑣,𝑖
solute overall mass transfer coefficient, 𝑃 phase ratio, 𝐶𝑒𝑞𝑆,𝑖 the solid phase concentration
in equilibrium with the bulk concentration. 𝑟𝑏,𝑖 and 𝑟𝑠,𝑖 are the net concentration change
due to refolding reaction in bulk and solid phases with details presented in section 3.2.2.
The solute solid phase concentration in equilibrium with the bulk concentration was
treated as a linear equilibrium relationship with a fixed equilibrium constant [10]:
𝐶𝑒𝑞𝑆,𝑖 = 𝐾𝑒𝑞,𝑖 𝐶𝑏,𝑖

(3-3)

where 𝐾𝑒𝑞,𝑖 is the equilibrium constant.
The boundary and initial conditions used to solve equations (3-1) and (3-2) are:
𝐶𝑏,𝑖 (𝑡, 0− ) = {

𝐶𝑓,𝑖 0 < 𝑡 < 𝑡𝑝𝑢𝑙𝑠𝑒
0
𝑡 > 𝑡𝑝𝑢𝑙𝑠𝑒

(3-4a)

𝜕𝐶𝑏,𝑖
(𝑡, 𝐿𝐶 ) = 0
𝜕𝑥

(3-4b)

𝐶𝑏,𝑖 (0, 𝑥) = 0

(3-4c)

𝐶𝑠,𝑖 (0, 𝑥) = 0

(3-4d)

where 𝐶𝑓,𝑖 is solute concentration in feed, 𝑡𝑝𝑢𝑙𝑠𝑒 is the duration of sample injection, and
𝐿𝐶 is the column length. The assumption that the sample is introduced into the column as
a rectangular pulse of length 𝑡𝑝𝑢𝑙𝑠𝑒 may not be valid in most practical applications.
However, as the injection time is very small compared to retention time, such
simplification still seems to be applicable [22].
To solve the above system, the first and second spatial derivatives were discretized using
fourth-order finite difference equations except for boundary points for which second
order forward and backward finite difference approximations were used. The resulting
method of lines system of ODEs was solved numerically in MATLAB by ode15s solver.
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3.2.1 Determination of Model Parameters
The axial dispersion coefficient was calculated based on the definition of the Peclet
number, which was estimated using the correlation of Chung and Wen for small Reynold
numbers as follows [5]
𝐷𝐿 =

𝑢𝐿𝑐
𝑃𝑒

(3-5a)

𝑃𝑒 =

0.1𝐿𝑐
𝑅𝑝 𝜀𝑏

(3-5b)

where 𝑅𝑝 is particle radius and 𝜀𝑏 is bed void volume fraction which was measured using
thyroglobulin from bovine thyroid as a test probe
𝑉0
𝑉𝑐

𝜀𝑏 =

(3-6)

where 𝑉0 and 𝑉𝑐 are the elution volume of thyroglobulin from bovine thyroid and column
volume respectively, correcting by subtracting the system volume such as tubing and
valves. The phase ratio (void to non-void volume) is
𝑃=

1 − 𝜀𝑏
𝜀𝑏

(3-7)

The mass transfer and equilibrium constants (𝑘𝑜𝑣,𝑖 and 𝐾𝑒𝑞,𝑖 ) were found by minimization
of the deviation of measured concentration vs. calculated in a least squares sense using
fmincon function in MATLAB with an additional constraint for recovery (𝑅𝑏,𝑖 ≤1) which
was defined as
𝑗=𝑛

𝑓(𝑥) =

𝑅𝑏,𝑖=

𝑒𝑥𝑝,𝑗
∑(𝐶𝑏,𝑖
𝑗=1

−

(3-8)

𝑓𝑖𝑡,𝑗
𝐶𝑏,𝑖 (𝑥))2

𝑀𝑖
𝐶𝑓,𝑖 𝑉𝑝𝑢𝑙𝑠𝑒

(3-9)
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𝑒𝑥𝑝
where 𝑥 is a vector of mass transfer and equilibrium constants, 𝐶𝑏,𝑖
the vector of

experimental solute concentration at the column outlet, 𝑛 the number of elements in
concentration vector, 𝑀𝑖 sum of mass of solute collected in fractions and 𝑉𝑝𝑢𝑙𝑠𝑒 is
injection volume.The initial guesses for these parameters were estimated as follows:
𝐾𝑒𝑞,𝑖 = 𝑘𝑠𝑒𝑐,𝑖 =

𝑉𝑒,𝑖− 𝑉0
𝑉𝑡 − 𝑉0

(3-10)

where 𝑘𝑠𝑒𝑐,𝑖 is the average distribution coefficient (size exclusion capacity) of solute,
𝑉𝑒,𝑖 is its elution volume and 𝑉𝑡 is total porosity volume of the column determined by
pulse injection of acetone.
Freydell et al. [5] have provided a complete list of references which report correlations
for calculation of protein free diffusivity, pore diffusivity and film mass transfer
coefficient in order to calculate 𝑘𝑜𝑣 .The hydrodynamic radius of the solute is necessary
to estimate the above parameters. In the same paper, they proved the adequacy of
extended-Ogston model to correlate average distribution coefficient to the hydrodynamic
radius of proteins in two different gel materials namely Superdex75 and Sephaseryl 100.
In this work, the same model was used to construct a calibration curve for the size
exclusion column and find the molecular size of various species. This method is an
efficient way to measure molecular size of kinetic species involved in a refolding
reaction.
Finally, the kinetic constants in the rate terms were determined by minimizing 𝑓(𝑥)for
recovered native protein elution profiles with constrain of refolding yield (𝑌𝑏 ≤1) which
was defined as
𝑌𝑏 =

𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝐶𝑓,𝑈 𝑉𝑝𝑢𝑙𝑠𝑒

(3-11)

where 𝑀𝑛𝑎𝑡𝑖𝑣𝑒 is sum of native protein mass collected in fractions and 𝐶𝑓,𝑈 is unfolded
lysozyme concentration in feed.
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3.2.2 Reaction Scheme
An adequate kinetic scheme is required to predict the on-column refolding results.
Deviation of lysozyme refolding, in low denaturant environment (e.g up to 1 M urea),
from two-state kinetics behaviour (cooperative refolding) is evident and its refolding
involves at least one intermediate both for denatured and denatured/reduced forms of the
protein [13,23–26]. However, lysozyme refolding kinetic data has been interpreted in
many different ways and more than one “pathway model” can fit the experimental results
[23]. Some research work suggests the existence of parallel refolding pathways which is
justified by heterogeneity of unfolded state and includes a fast direct refolding from
unfolded to native state and a slow refolding through formation of intermediates.
However, only small fractions of molecules seem to follow the direct pathway [13,24,25].
Nevertheless, the refolding of reduced and denatured lysozyme has been successfully
modeled using a single dominant reaction pathway in batch and fed batch refolding
[14,15]. The reaction mechanism is shown in Figure 3-1; it is suggested that early
intermediates with only a fraction of disulfide bridges are rapidly formed during
“collapse process” followed by formation of native-like intermediates and a slow
conversion of these intermediates to the native state [13].

Figure 3-1. Lysozyme refolding kinetic scheme, U: unfolded protein, Ie: early
intermediates, IN: native-like intermediates and N: native protein.
According to this scheme the reaction rates for both bulk (𝑟𝑏,𝑖 ) and solid (𝑟𝑠,𝑖 ) phases in
equations (3-1) and (3-2) are as following
𝑟𝐼𝑒 = −𝑘1 𝐶𝐼𝑒

(3-12a)

𝑟𝐼𝑁 = 𝑘1 𝐶𝐼𝑒 − 𝑘2 𝐶𝐼𝑁

(3-12b)
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𝑟𝑁 = 𝑘2 𝐶𝐼𝑁

(3-12c)

Furthermore, formation of misfolded lysozyme with non-native contact, presumably
incorrect disulfide bridges, has also been previously observed [8,27] and therefore might
be included in the reaction mechanism. However, in this work very small fraction of
misfolded protein was observed over the course of experiments. The misfolded species
also slowly convert to native state [27] and therefore their formation was neglected for
the purposes of this work.

3.3 Materials and Methods
3.3.1 Chemicals
Reagent grade Bovine Serum Albumin (BSA), ʟ-arginine and urea, Ethylene Diamine
Tetra Acetic acid (EDTA), lysozyme from chicken egg white, trizma® base (Tris-base),
ʟ-cysteine, ʟ-cystine, BioUltradithiothreitol (DTT) solution, Micrococcus lysodeikticus,
potassium phosphate monobasic, BioXtra sodium chloride, Trifluoric acetic acid (TFA)
reagent plus grade and acetonitrile 0.1% TFA were purchased from Sigma-Aldrich,
Canada. Red 660™ protein assay reagent was purchased from G-Biosciences, USA.
Superdex™75pg resin (34 µm average particle size) was purchased from GE Healthcare,
Canada.

3.3.2 Analytical Methods
3.3.2.1

UV Absorption

Samples of native protein were prepared in 0.1 M phosphate solution buffered at pH 7 in
order to determine the purity and lysozyme percentage of powder. The concentration of
native lysozyme was determined with ultraviolet (UV) absorption spectroscopy
(Shimadzu UV-3600) using extinction coefficient of 2.63 ml/mg/cm [27]. The
concentration of native lysozyme standards prepared in refolding buffer was determined
accordingly. The concentration of native protein in fractions collected during nonreactive native experiments was determined by using a Tecan M200 plate reader.
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BSA standards were prepared in refolding buffer using 96% BSA powder and
concentration of BSA in collected fractions were determined by comparing the fractions
and standard protein samples UV absorbances using the plate reader.

3.3.2.2

Native Lysozyme Concentration

A Vydac 214MS C4 column (5 µm, 250 x 4.6 mm) was used on an Agilent HPLC system
to separate native protein from other conformations and determine its concentration in
collected samples during reactive experiments. A linear acetonitrile-water gradient with
0.1% (v/v) TFA starting at 25% acetonitrile increasing at 2.3%/min was used to elute the
protein in 10min. The total solvent flow rate, column temperature and injection volume
were set at 1 mL/min, 20 ºC and 50 µL respectively.

3.3.2.3

Enzymatic Activity and Total Protein Concentration

The enzymatic activity of fractions was compared with activity of standard protein
samples. The enzymatic activity of samples and standards were measured by recording
the linear decrease of cell suspension absorbance (0.3 mg/mL Micrococcuslysodeikticusin 0.1 M phosphate buffer, pH 7) at 450 nm after mixing using a
microtiterplate reader after shaking for 40s [8].
The total protein concentrations in samples were determined using Red 660™ protein
assay in which 10 µl protein samples was transferred to each well, 150 µL of reagent was
added and mixed (6.5 mm circular shaker)using the plate reader, and absorbance of the
mixture at 660 nm was measured after 5 min. The total protein concentrations were
calculated by comparing the fraction and standard protein sample absorbance.

3.3.3 Feed Preparation
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1)
was used to prepare various concentrations of denatured/reduced lysozyme (2-20
mg/mL). The excess of DTT was used to assure complete reduction of disulfide bridges.
The sample was incubated for 2 h at 37 °C [8] and loss of native structure was confirmed
by RP-HPLC analysis afterwards.
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3.3.4 Experimental Set up
A XK16/40 column (GE healthcare, Canada) was packed with Superdex™75pg resin
(column volume ~54 mL). The packed column was installed on ÄKTA purifier 100
controlled by UNICORN 5.31 software and equipped with online pH probe, UV detector
and conductivity cell. The fractionation kit allows the collection of samples at desired
volumes. Acetone pulse injection (2% (v/v)) was used to test the packing quality by
comparing the peak symmetry and number of theoretical plates per length of column with
manufacturer recommended criteria. Column void volume is commonly determined by
blue dextran; however it was observed that blue dextran binds to superdex75pg and does
not elute from the column despite using recommended concentration of salt in the mobile
phase. Therefore, thyroglobulin from bovine thyroid (669 kDa) which is completely
excluded from the macropores of Superdex75pg (fraction range of 3-70 kDa) was
injected on the column to measure the void fraction.

3.3.5 SEC Non-reactive Experiments
Various concentrations and volumes of native lysozyme was injected on the column
equilibrated with 2 column volumes (CV) of a refolding buffer identical to buffer used
for reactive experiments. The protein was eluted using the same buffer and 1mL/min flow
rate while 0.5 mL fractions were collected for UV absorbance analysis to determine the
native protein concentration in each fraction. The model parameters for native species
were fitted against these experimental results. Refolding buffer A was composed of 0.1
M Tris, 1 mM EDTA, 2 M urea, 0.2M ʟ-arginine, 3 mM cysteine, 0.3 mM cysteine
buffered at pH 8.1 while in refolding buffer B, ʟ-arginine is replaced by 0.1 M NaCl to
investigate the implication of removing ʟ-arginine in terms of mass transfer parameters
and kinetics of refolding. The addition of NaCl was necessary to prevent non-specific
interactions with the column [7,20].
The redox couple was then removed from buffer A to quench the refolding at early
intermediates [28,29] and fit the model parameters for these species. Fractions of 0.5 mL
were collected and analyzed using total protein assay.
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Native-like intermediates of lysozyme have been recovered in batch experiments by acidquenching and HPLC separation of samples recovered at later stages of refolding [13].
Alternatively, it may be possible to gain information on the structure of kinetically shortlived intermediates by performing equilibrium experiments [23]. In the case of lysozyme,
the characteristics of kinetic native-like intermediates formed in refolding of denatured
and denature-reduced hen egg lysozyme are very similar [13] and equilibrium
intermediate has been detected in unfolding experiments using urea where native-like
intermediates showed the highest population at 4M urea [30]. Therefore equilibrium
studies were performed to find the model parameters for native-like lysozyme. The
column was equilibrated with 2 CVs of buffer C (0.1 M Tris, 1 mM EDTA, 4 M urea, 0.2
M ʟ-arginine) and the same buffer was used to dissolve lysozyme which was incubated
over night at 37 ºC. The protein was eluted using 0.5mL/min flow rate to avoid high
pressure drop due to the high concentration of urea present in the equilibrium buffer C.
Fractions of 0.5 mL were collected and analysed using total protein assay.

3.3.6 SEC Refolding- Reactive Experiments
The column was equilibrated with 2 CVs of the refolding buffer A and various volumes
(0.5 and 1 mL) and concentrations (5, 10 and 20 mg/mL) of denatured/reduced lysozyme
was injected and eluted using the same buffer and flow rate of 1mL/min with exception
of one run where 0.5mL/min flow rate was used. The above loading concentration range
was selected based on previous studies which demonstrated no aggregation formation
within this range [31]. Fractions of 1mL were collected and analyzed using RP-HPLC to
determine the concentration of correctly refolded protein. The enzymatic activity and
total protein analysis were also carried out for some reactive experiments to gain more
information on characteristics of recovered species.
For reactive experiments without ʟ-arginine, the column was equilibrated with 2 CVs of
the refolding buffer B and various volumes (0.5, 1 and 2 mL) of 2 and 5 mg/mL
denatured/reduced lysozyme were injected and eluted with the same buffer. Low loading
concentrations were selected to assure no aggregates were formed. Fractions of 1mL
were again collected and analysed using RP-HPLC.
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All the buffers were prepared fresh using ultra-pure water (Barnstead easy-pure RODI
equipped with 0.2 µm filter, Fisher Scientific), filtered again with a 0.2 µm membrane
and de-gassed prior to use. The column was washed with 2 CVs de-ionized water after
final elution.

3.4 Results and Discussion
3.4.1 Non-reactive Experiments
The average experimental distribution coefficient (𝑘𝑠𝑒𝑐,𝑁 ) and fitted values for the
equilibrium solid phase concentration (𝐾𝑒𝑞,𝑁 ) and the overall mass transfer coefficient
(𝑘𝑜𝑣,𝑁 ) of the native protein using buffers A and B are reported in Table 3-1. In both
cases, 𝐾𝑒𝑞,𝑁 is less than 𝑘𝑠𝑒𝑐,𝑁 . Figure 3-2 shows the satisfactory agreement between
experimental and predicted results for native protein elution profiles. Reduced average
distribution coefficient, equilibrium solid phase concentration and overall mass transfer
coefficient when buffer A is used compared to buffer B, indicated a larger apparent
radius of native protein in the presence of ʟ-arginine. Vagenende et al. reported similar
results and explained this observation based on formation of “dynamic arginine-protein
associated clusters” extended from the surface of the protein [16]. As discussed earlier,
the apparent radius was extrapolated using column calibration curve (Figure 3-3) based
on extended-Ogston model. The lysozyme hydrodynamic radius measured in this work is
larger than some reported values [30] as lysozyme swells in the presence of urea but is
consistent with results reported for urea [32].
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Table 3-1. Average distribution coefficient, fitted model parameters and apparent radius
of kinetic species formed during lysozyme refolding. Solute 𝒊 is native lysozyme for first
and second row early and native-like intermediates for third and fourth row respectively.
Buffer

𝑘𝑠𝑒𝑐,𝑖 (-)

𝐾𝑒𝑞,𝑖 (-)

𝑘𝑜𝑣,𝑖 (min-1)

Apparent rh
(nm)

A

0.55±0.01

0.44±0.003

17.29±1.99

1.8

B

0.58±0.01

0.49±0.002

21.61±1.55

1.7

A and B

0.08±0.01

0.08±0.004

2.69±0.45

3.5

C

0.47± 0.004

0.39±0.001

16.19±0.22

2

Figure 3-2. Experimental vs. predicted native protein elution profiles using buffer A (top
row) and B (bottom row).
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Figure 3-3. Size exclusion column calibration curve based on extended-Ogston model.
Quenched experiments were carried out to determine model parameters. Figure 3-4A
shows the agreement between experimental and predicted elution profiles of early
intermediates using fitted (least squares) values of 0.24±0.002 and 14.37±1.97 min-1
respectively. However, early intermediates under quenching conditions showed a higher
elution volume compared with reactive experiments (Figure 3-6A). This may be due to
increased non-specific interaction at higher concentration of early intermediates with the
gel in quenched experiments compared to short-lived early intermediates in reactive
experiments. However, this is in contrast with that presented in our previous work [31]
where the same elution volumes were observed and suggest that Superdex75pg surface
properties changes over time well before expiry of the gel as indicated by manufacturer
(~ 2 years ). Binding of blue dextran to the gel during void volume measurements (as
mentioned before) was another indication of such change over time. The recovered
protein still did not show any enzymatic activity and the florescence intensity was higher
than native protein (data not shown). Since elution position of early intermediates was
seemingly affected by interactions with the gel matrix during quenched experiments, the
model parameters were fitted for BSA protein (66.5 kDa) elution profiles and used as a
model compound (Figure 3-4B). BSA was used because it showed the same elution
volume as early intermediates in reactive experiments suggesting the same extent of
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exclusion within fraction range of the gel. As shown in Figure 4B, the elution volume of
BSA was not influenced by the type of refolding buffer and the same model parameters
were fitted for when buffer A or B were used as reported in Table 3-1.

Figure 3-4. (A) Experimental vs. predicted early intermediate elution profiles using
buffer A without redox couple to quench the reaction at early intermediates (B)
Experimental vs. predicted BSA elution profile used as a model compound to find model
parameters for early intermediates.
Figure 3-5 shows the elution profiles of lysozyme equilibrated in refolding buffer C. As
described in section 3.3.5 the model parameters and size information for native-like
intermediate were calculated using equilibrium studies (summarized in Table 3-1).
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Figure 3-5. Experimental vs. predicted elution profiles of lysozyme equilibrated in
buffer-C.

3.4.2 Reactive Experiments
Three protein conformations were recovered in reactive experiments using refolding
buffer A, as shown in Figure 3-6A.

Figure 3-6. (A) Chromatogram of refolding of lysozyme using refolding buffer A (L=10
mg/mL, Vpulse=1 mL) and (B) Chromatogram of protein pool obtained from reactive
experiment of (A).
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The first peak is associated with early intermediates with no enzymatic activity. The
second and third peaks showed similar enzymatic activity based on measurement with
enzymatic activity and total protein assays. However, considering the elution profile of
the recovered protein pool (Figure 3-6B), it is obvious that only one peak corresponds to
native lysozyme eluting at the same volume as non-reactive native protein injections and
the peak eluting before that was characterized as misfolded protein. It can be observed on
Figure 3-6A that fractions containing early intermediates also contain misfolded protein
(overlapping peaks) and quantification of either early intermediate or misfolded was not
possible by HPLC analysis due to unavailability of standards for these species. The
difference between total protein concentration and native protein is the summation of
these two species and they cannot be quantified individually. This highlights the need for
conducting quenched experiments or use of a model compound such as BSA to find
model parameters to provide estimates for early intermediates.
A simplified reaction scheme considering native-like intermediate to native protein as the
rate-limiting step was initially used to find the reaction rate constants and simulate the
results of on-column refolding in this work. However, as shown in Figure 3-7 it was
observed that this mechanism does not produce a satisfactory agreement between
experimental and predicted values due to exclusion of early collapsed to native-like
intermediate step from refolding reaction.

49

Figure 3-7. Experimental vs. predicted native protein elution profiles recovered during
reactive experiments using a simplified reaction scheme from native like intermediate to
native lysozyme.
On the other hand, an apparent two-state refolding representation of the reaction
mechanism including early collapsed intermediates to native protein showed a
satisfactory fit as shown in Figure 3-8. For one case of low flow rate (0.5 mL/min), the
same mass transfer parameters as higher flow rate (1 mL/min) were used because
estimated film and pore mass transfer resistances (determined using correlations)
revealed the pore resistance as the major resistance component and this value is
independent of velocity [10].
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Figure 3-8. Experimental vs. predicted native protein elution profiles recovered during
reactive experiments where an apparent two- state representation of reaction mechanism
was used.
The apparent reaction rate constant was found to be 0.08±0.01 min-1 and 0.1±0.01 min-1
for refolding with buffer A and B respectively, indicating that the low concentration of ʟarginine utilized in this work prevented aggregation without compromising the speed of
the reaction (values are identical at 95% statistical significance). It should be noted that
the disagreement between experimental and model prediction at the tail of the peak is due
to non-specific interactions with the gel, which were not accounted for in the model.
From these results it is evident that disappearance of the early intermediates is not
immediate. Gradual removal of denaturing and reducing agents in SEC and the chemical
composition used in this work may explain this behavior of the protein. For example,
higher local concentration of chaotropic molecules such as urea has shown reduced
apparent kinetics [33]. However, higher local concentration of such molecules and their
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gradual removal protects early intermediate species against aggregation resulting in
advantage of SEC over dilution refolding. In addition, carryover of excess concentration
of reducing agent used in feed preparation can lead to suboptimum concentration ratio of
redox couple and slow reformation of native disulfide bridges [8].
One should bear in mind that although the assumption of constant kinetics was proved
applicable in this work, it may not be valid in higher loading volumes and reaction rate
term may be more accurately determined via local concentrations of denaturing and
reducing agents [6,33]. For example the full potential of SEC for protein refolding is
realized in the application of continuous processing configurations such as simulated
moving bed which normally results in less dilution and higher local concentrations [6].
Similarly, although no aggregates were formed at concentrations studied in this work the
possibility of aggregation must be considered at higher loading volumes and local
concentrations of protein.

3.5 Conclusion
The fundamental studies of oxidative protein refolding in SEC in this work showed: 1) an
apparent two-state refolding mechanism adequately describes the refolding of model
protein lysozyme on SEC highlighting the importance of chemical composition of the
refolding environment and the rate by which this composition changes on kinetics of
refolding; 2) different methods that can be used to find characteristic information about
species involved in a refolding reaction such as quenched and equilibrium experiments
and use of model compounds which is essential for model development and simulation of
protein refolding on SEC; 3) examination of effect of ʟ-arginine on characteristics of
protein conformations showed higher apparent radius of the native lysozyme and no
apparent change on larger protein conformations such as early intermediates and BSA at
the presence of this additive; 4) low concentration of ʟ-arginine used in this work (0.2 M)
combined with 2 M urea showed insignificant effect on the rate of refolding reaction.
This is of particular interest due to extensive application of these compounds as
aggregation suppressor additives.
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The same model can be extended to higher loading volumes or protein concentrations
provided that the effect of local concentration of denaturing and reducing agents and local
protein concentration on kinetics of refolding and aggregation are incorporated into the
model.
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4 Oxidative Protein Refolding on Size Exclusion
Chromatography: From Batch Single-column to Multi-column
Counter-current Continuous Processing
Abstract
Recently size exclusion chromatography (SEC) used in multi-column continuous
simulated moving bed (SMB) configurations (hereinafter SMB-SEC) has been
investigated for protein refolding at industrial scale. This is due to several advantages
offered by SMB configurations particularly when process parameters are thoroughly
screened and optimized. A robust mathematical model is essential for high-throughput
process screening and optimization. In this work, a previously investigated single-column
mathematical model was modified to extend its applicability for protein oxidative
refolding/aggregation predictions in SMB-SEC. The model considers a wider loading
concentration range of the model protein (lysozyme) on SEC. The potential influences of
high concentrations of chaotropic reagents on kinetic and thermodynamic model
parameters have been discussed based on previous experimental results and their
predicted local concentrations through the SMB-SEC columns and at the product steam.
It was observed that aggregation occurs when local protein concentration exceeds a
critical concentration. No urea recovery at the product stream indicated that the refolding
reaction will continue off-column to recover the native- protein product. Therefore, it is
suggested that the developed model is tested against experimental results for total
solubilized protein (early intermediates and native conformations) and process
performance indicators are defined based on solubilized protein.

4.1 Introduction
Despite the advances made to date for expression of protein-therapeutics using E-coli [1],
existing technologies to recover active and high-purity product still incur significant costs
due to low product concentration and high buffer consumption during conventional batch
dilution refolding process resulting in low volumetric productivity [2]. As an alternative
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due to the gradual separation of unfolded protein molecules from denaturing and reducing
agents and their separation from solubilized aggregates in SEC, which in turn results in
high refolding yield and purity, SEC has been widely used at lab scale [3–9]. However,
this method in form of single-column batch processing may not enhance the
aforementioned process performance indicators for industrial scale production of E-Colibased protein-therapeutics. On the other hand, a multi-column continuous simulated
moving bed system offers several advantages compared to single-column batch operation
including increased productivity per unit mass of solid phase, lower solvent consumption,
and less diluted products. This configuration consists of a set of chromatographic
columns connected in series and is operated in continuous mode; the inlet/outlet lines are
periodically shifted synchronously in the direction of liquid-phase flow to mimic
countercurrent movement between a liquid-solvent and a solid phase. Multi-column
continuous simulated moving bed is a well-established process for intensified difficult
separations of small molecules and fine products e.g. separation of enantiomers [10,11].
However, its application for protein refolding and separation has recently attracted the
attention of researchers [3–5,7]. For example, Freydell et al. [5] have reported a 35 times
increase in productivity and 1/10 solvent consumption when a SMB-SEC was used for
refolding of a model fusion protein compared to single-column processing.
Since many parameters are involved in operating a SMB-SEC (i.e. internal and external
flow rates, switching time and feed concentration) systematic optimization studies are
required to exploit the full potential of this system. A mathematical model is a prerequisite for screening of process parameters and optimization. Freydell et al. [5] used a
previously investigated single-column model in order to predict refolding/aggregation of
a fusion protein in a four-zone SMB-SEC configuration comprised of multiple columns
connected in series. They observed considerable discrepancy between model predictions
and experimental results. For instance, the refolding yield was over-predicted by a factor
of three. As discussed in the same work, this disagreement can be related to lower
dilution factor in SMB-SEC compared to a batch single-column refolding resulting in
higher local concentration of chaotropic agents (urea and DTT). And, in order to improve
the SMB-SEC model- predictions in terms of native protein recovery the influence of
local concentration of urea and DTT on model parameters should be considered.
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The effect of lower dilution factor is twofold, as in addition to higher local concentrations
of chaotropic reagents it also results in higher local protein concentration compared to a
batch single-column refolding. Higher local protein concentration may additionally result
in different reaction schemes. For example if for a single-column refolding experiment no
aggregation was observed there would still remain the possibility of aggregation in SMBSEC at the same protein loading concentrations.
In this work, (1) a previously experimentally verified single-column model was modified
to expand its applicability for prediction of oxidative protein refolding/aggregation on
SMB-SEC by considering a wider protein loading concentration range and the additional
model parameters resulting from this modification were determined experimentally; (2)
the sensitivity of refolding kinetics and possible complexity arising from reducing agent
(DTT) carry-over have been discussed and DTT-free refolding was investigated and
compared to previous studies with DTT carry-over; (3) the denaturing reagent (urea)
mass transfer parameters were measured experimentally and used to predict the
concentration of urea through SMB-SEC columns and at the product outlet under the
current operation conditions; (4) the suitability of the developed model for process
optimization was investigated; and (5) the effect of SMB-SEC operating parameters
namely loading concentration and switching time on process performance indicators were
predicted and the results were compared to single-column oxidative refolding of
lysozyme.

4.2 Mathematical Model and Theory
4.2.1 Column Model
The protein refolding in size exclusion column was modeled using dispersive transport in
the bulk with a film linear mass transfer resistance between particle-solid and bulk-liquid
phases. The formulated differential mass balances for solutes in the bulk and the solid
phases are [6].
𝜕𝐶𝑏,𝑖
𝜕 2 𝐶𝑏,𝑖
𝜕𝐶𝑏,𝑖
= 𝐷𝐿
−𝑢
− 𝑃𝑘𝑜𝑣,𝑖 (𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖 ) + 𝑟𝑏,𝑖
2
𝜕𝑡
𝜕𝑥
𝜕𝑥
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(4-1)

𝜕𝐶𝑠,𝑖
= 𝑘𝑜𝑣 (𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖 ) + 𝑟𝑠,𝑖
𝜕𝑡

(4-2)

where 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖 are the concentration of solute 𝑖 (unfolded, intermediates and native
conformations) in bulk and solid phase respectively. In equations (4-1) and (4-2),
𝑡 represents time, 𝑥 axial distance along the column, 𝐷𝐿 axial dispersion coefficient, 𝑢
interstitial velocity, 𝑘𝑜𝑣,𝑖 solute overall mass transfer coefficient, 𝑃 phase ratio, 𝐶𝑒𝑞𝑆,𝑖 the
solid phase concentration in equilibrium with the bulk concentration. 𝑟𝑏,𝑖 and 𝑟𝑠,𝑖 are the
net concentration change due to refolding and aggregation reactions in bulk and solid
phases, which are described further in section 4.2.3.
The solute solid phase concentration in equilibrium with the bulk concentration was
treated as a linear equilibrium relationship with a fixed equilibrium constant [12]:
𝐶𝑒𝑞𝑆,𝑖 = 𝐾𝑒𝑞,𝑖 𝐶𝑏,𝑖

(4-3)

where 𝐾𝑒𝑞,𝑖 is the equilibrium constant.
The boundary and initial conditions used to solve equations (4-1) and (4-2) are:
𝐶𝑏,𝑖 (𝑡, 0− ) = {

𝐶𝑓,𝑖 0 < 𝑡 < 𝑡𝑝𝑢𝑙𝑠𝑒
0
𝑡 > 𝑡𝑝𝑢𝑙𝑠𝑒

(4-4a)

𝜕𝐶𝑏,𝑖
(𝑡, 𝐿𝐶 ) = 0
𝜕𝑥

(4-4b)

𝐶𝑏,𝑖 (0, 𝑥) = 0

(4-4c)

𝐶𝑠,𝑖 (0, 𝑥) = 0

(4-4d)

where 𝐶𝑓,𝑖 is solute concentration in feed, 𝑡𝑝𝑢𝑙𝑠𝑒 is the duration of sample injection, and
𝐿𝐶 is the column length. The assumption that the sample is introduced into the column as
a rectangular pulse of length 𝑡𝑝𝑢𝑙𝑠𝑒 was initially used as it has proven applicable in some
cases [6,13]. However, the experimental injection profile was later introduced by a
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Gaussian distribution function to further improve the accuracy of the model parameters
and prediction results.
To solve the 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖 along 𝑥 at different times, the first and second spatial
derivatives were discretized as fourth-order central finite difference equations except for
boundary points where second order forward and backward finite difference
approximations were used. The resulting system of ODEs in time (method of lines) was
solved numerically in MATLAB.

4.2.2 SMB-SEC Model
The selected design parameters of SBM-SEC model (e.g. number of columns in each
zone and column dimensions) in this work were identical to the system used by Freydell
et al. [5]. Figure 4-1 is a schematic representation of their system. Each zone comprises
of two columns connected in series and as shown on the same figure an open loop system
was used.
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Figure 4-1. Schematic representation of a four-zone SMB-SEC: QD, QEx, QRa, QF and QW
are buffer, extract, raffinate, feed and waste flow rates respectively. Qj is internal flow
rate in zone j: 1-4)
The dimension of each column is 1 cm i.d and packed bed height of ~8 cm. Each column
was modeled with the same approach as for single column except that boundary
conditions are taken as periodic. The changing boundary condition is simulated by
hypothetical movement of solid (direction shown on Figure 4-1) or more accurately
switching columns’ positions after each switching time. The boundary condition for each
node is then:
𝐶𝑏,𝑖 (𝑡, 𝐿+1 ) = 𝐶𝐷,𝑖

(4-5a)

𝐶𝑏,𝑖 (𝑡, 𝐿+2 ) = 𝐶𝑏,𝑖 (𝑡, 𝐿−1 )

(4-5b)
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𝐶𝑏,𝑖 (𝑡, 𝐿+3 ) =

𝑄𝐹 𝐶𝑓,𝑖 + 𝑄2 𝐶𝑏,𝑖 (𝑡, 𝐿−2 )
𝑄3

(4-5c)

𝐶𝑏,𝑖 (𝑡, 𝐿+4 ) = 𝐶𝑏,𝑖 (𝑡, 𝐿−3 )

(4-5d)

where 𝐶𝐷,𝑖 is the concentration of solute 𝑖 in the refolding buffer.

4.2.3 Reaction Scheme
The refolding of reduced/denatured lysozyme has been successfully modeled using a
single dominant reaction pathway in batch and fed batch refolding [14,15]. The reaction
mechanism is shown in Figure 4-2.

Figure 4-2. Lysozyme refolding and aggregation kinetic scheme, U: unfolded protein Ie:
early intermediates, IN :native-like intermediates, N: native protein, An : aggregates (n: 2
and 3).
It is suggested that early intermediates with only a small fraction of disulfide bridges are
rapidly formed during “collapse process”, followed by formation of native-like
intermediates and a slow conversion of these intermediates to native state [16]. Since
early intermediates are more susceptible to aggregation compared to native-like
intermediates, aggregation is considered the result of early intermediate species
association via sequential polymerization mechanism [6,14,15]. In our previous work,
lysozyme refolding on SEC could be well described by an apparent two state mechanism
involving early intermediates and native lysozyme [17]. Furthermore when lysozyme was
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refolded without ʟ-arginine additive, only one size of solubilized aggregates was
recovered [18], therefore it was assumed that only one size of aggregate is also formed in
the presence of ʟ -arginine and aggregation was then regarded as a second order reaction.
According to this simplified scheme the reaction rates for bulk (𝑟𝑏,𝑖 ) and solid (𝑟𝑠,𝑖 )
phases in equations (4-1) and (4-2) are as following
𝑟𝐼𝑒 = −𝑘𝑎𝑝𝑝 𝐶𝐼𝑒 − 2 𝑘𝑎 (𝐶𝐼𝑒 )2

(4-6a)

𝑟𝐼𝑁 = 𝑘𝑎𝑝𝑝 𝐶𝐼𝑒

(4-6b)

𝑟𝐴2 = 𝑘𝑎 (𝐶𝐼𝑒 )2

(4-6c)

where

𝑘𝑎𝑝𝑝 and

𝑘𝑎 are apparent refolding and aggregation kinetic constants

respectively.
Aggregation occurs at higher local concentrations which might be purely due to increased
aggregation kinetics competing with refolding reaction or surpassing early refolding
kinetic species solubility [19]. In the former case, the thermodynamic condition for
aggregation formation is always satisfied while for the latter there is a critical
concentration above which aggregates are formed. Elution profiles of refolded native
protein for lysozyme refolding on SEC for a wide protein loading concentration range (550mg/mL) are examined in this work to investigate both case scenarios, assessed through
inclusion of these effects in the model through an aggregation kinetic constant (𝑘𝑎 ) and
early intermediate solubility (𝐶𝑠 ). If a critical concentration is required to describe the
results of refolding/aggregating on SEC, the aggregation rate is modelled as following
𝑘𝑎 (𝐶𝐼𝑒 )2 𝐶𝐼𝑒 ≥ 𝐶𝑠
𝑟𝐴2 = {
0
𝐶𝐼𝑒 < 𝐶𝑠

(4-6d)

4.2.4 Model parameters estimated by single-column experiments
In our previous work an axial dispersion coefficient was calculated using available
correlations for packed bed column. Also, the void volume, which was necessary for
axial dispersion coefficient and phase ratio calculations, was measured using
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thyroglobulin from bovine thyroid as a test probe. Furthermore, the mass transfer and
equilibrium constants for early intermediates and native lysozyme (𝑘𝑜𝑣,𝑖 and 𝐾𝑒𝑞,𝑖 ) were
found by least-squares fitting of the deviation of measured concentration during singlecolumn experiments vs. calculated for BSA model protein and native lysozyme
respectively. The refolding kinetic constant (𝑘𝑎𝑝𝑝 ) was also obtained in the same manner
for elution profile of refolded native lysozyme when low loading concentrations (5-20
mg/mL) of denatured/reduced lysozyme were refolded on SEC. Low loading
concentrations were used to prevent aggregation [17].
In this work, In order to introduce aggregation into the model, the aggregation kinetic
constant (𝑘𝑎 ) and early intermediate solubility (𝐶𝑠 ), were determined by least squares
fitting of measured refolded native protein concentration vs. calculated (equation 4-7)
accomplished via the fminsearch function of MATLAB to find the parameters which
indicated a global minimum.
𝑗=𝑛

𝑒𝑥𝑝,𝑗

𝑓(𝑥) = ∑𝑗=1 (𝐶𝑏,𝑖

𝑓𝑖𝑡,𝑗

− 𝐶𝑏,𝑖 (𝑥))2

(4-7)

The above kinetic and thermodynamic parameters vary depending on local concentration
of urea and DTT. In order to investigate the concentration profile of urea in SMB-SEC,
mass transfer and equilibrium constants were found by measuring the concentration
profile of pure urea injection on single column and minimization of deviation of
experimental vs predicted results. The correlations for these constants have found to have
wide errors as shown in the work of Park et al. [7], which motivated experimental
determination of these values.

4.2.4.1

Effect of Denaturant and Reducing Agents on Model Parameters

The carry-over of both urea and DTT, present in the feed stream, to the refolding
environment can influence the results of refolding. However, it should be noted that DTT
exists in both oxidized and reduced forms, which each possess different effects on
refolding and aggregation kinetics. Concentrations equal or higher than of 0.6 mM of
reduced form of this reagent can completely stop the refolding of lysozyme, while both
the reduced and oxidized forms might result in non-optimal redox couple concentration
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ratio and indirect adverse effects [8]. Furthermore, the oxidized to reduced ratio of this
reducing agent will change over time due to oxidation unless continuous feed preparation
is implemented. The oxidized to reduced ratio is also dependent on the feed protein
concentration as the protein concentration varies whereas the initial concentration of DTT
in the feed is constant. For the above mentioned reasons the task of quantifying the
different effects becomes challenging. DTT may be removed before introducing the feed
stream to the continuous refolding system. In order to gain more information on possible
effects of DTT removal, batch single-column experiments of DTT-free lysozyme
refolding were executed and the results were compared to the cases with carry-over of
DTT.
The concentration profile of urea in SMB-SEC was predicted to find out more
information about its local concentrations through the columns and separation from
unfolded lysozyme. Since the purpose was to study the urea and protein concentrationwaves separation, no reaction was considered. This investigation assisted in deciding
whether further experimentations are required to find suitable functions to related kinetics
of on-column refolding, aggregation and solubility to urea local concentrations.

4.3 Materials and Methods
4.3.1 Chemicals
Reagent grade ʟ -arginine and urea, Ethylene Diamine Tetra Acetic acid (EDTA),
lysozyme from chicken egg white, trizma® base (Tris-base), cysteine, cystine,
BioUltradithiothreitol (DTT) solution, Trifluoric acetic acid (TFA) reagent plus grade
and acetonitrile 0.1% TFA were purchased from Sigma-Aldrich, Canada. DIUR-500 urea
assay kit and Red 660™ protein assay reagent were purchased from Bioassays, and GBiosciences, USA respectively. Superdex™ 75pg resin (34 µm average particle size) was
purchased from GE healthcare, Canada.
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4.3.2 Analytical Methods
4.3.2.1

Native-protein Concentration

A Vydac 214MS C4 column (5 µm, 250 x 4.6 mm) was used on an Agilent HPLC system
to separate native protein from other conformations and determine its concentration in
collected samples during protein refolding experiments on SEC. A linear acetonitrilewater gradient with 0.1% (v/v) TFA starting at 25% acetonitrile increasing at 2.3%/min
was used to elute the protein in 10 min. The total solvent flow rate, column temperature
and injection volume were set at 1 mL/min, 20 ºC and 50 µL respectively.
Concentration of native protein in samples collected during injection profile
determination was calculated by comparing the UV absorbance of samples and native
protein standards at 280 nm. Both standards and samples UV absorbance reading were
carried in a Tecan M200 plate reader.

4.3.2.2

Total-protein Concentration

The total protein concentration in protein pool after DTT removal was determined with
Red 660™ protein assay using microtiterplate reader in which 10 µl protein samples was
transferred to each well, 150 µL of reagent was added and mixed using the plate reader
(6.5 mm circular shaker), and absorbance of the mixture at 660 nm was measured after 5
min. The total protein concentrations were calculated by comparing the fraction and
standard protein sample absorbance.

4.3.2.3

Urea Concentration

The urea concentrations in samples were determined by urea assay kit (DIUR-500) using
microtiterplate reader in which 5 µl of diluted samples were transferred to each well, 200
µL of reagent was added and mixed using the plate reader (6.5 mm circular shaker), and
absorbance of the mixture at 520 nm was measured after 20 min. The samples were
diluted with water instead of refolding buffer to avoid the interference of ʟ -arginine with
the assay (as recommended by the manufacturer).
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4.3.3 Protein Unfolding
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1)
was used to prepare various concentrations of denatured/reduced lysozyme. The sample
was incubated for 2-4 h at 37 °C for lysozyme concentrations under 20 mg/mL [8] and
above 30 mg/mL respectively. The loss of native structure was confirmed by RP-HPLC
analysis afterwards.

4.3.4 Protein Injection Profile
The injection profile of protein was determined by replacing the column on ÄKTA
purifier 100 by a piece of tubing with the same dimensions as column inlet tubing. The
same injection loops were used for manual loading of native protein sample dissolved
and eluted with refolding buffer. Fractions of 200 µl were collected and the concentration
of native protein for each fraction was determined using UV absorbance.

4.3.5 DTT Removal
A 5 mL Hitrap desalting column (GE healthcare) was used to remove DTT from
denatured/reduced lysozyme. The column was equilibrated with 2 CVs of unfolding
buffer without DTT (0.1 M Tris-base, 1 mM EDTA, 6 M urea). 0.5 mL samples of 25
mg/mL were injected on column and eluted with 1 mL/min flow rate of unfolding buffer.
Fractions of 0.5 mL were collected and pooled for refolding experiments described in the
next section. In order to investigate the refolding of higher concentration of DTT-free
lysozyme, the pool of desalting stage was concentrated using 10K 4 mL Amicon® Ultra
centrifugal filters. The pool total protein concentration was determined using total protein
assay as described above.

4.3.6 Single-column Batch Refolding
A XK16/40 column (GE healthcare, Canada) packed with Superdex™75pg resins
(column volume ~54 mL) was installed on ÄKTA purifier 100 controlled by UNICORN
5.31 software and equipped with online pH probe, UV detector and conductivity cell. The
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fractionation kit allows the collection of samples at desired volumes. Acetone pulse
injection (2% (v/v)) was used to test the packing quality by comparing the peak
symmetry and number of theoretical plates per length of column with manufacturer
recommended criteria.
The column was equilibrated with 2 CVs of the refolding buffer (0.1 M Tris, 1 mM
EDTA, 2 M urea, 0.2M ʟ -arginine, 3 mM cysteine, 0.3 mM cysteine buffered at pH 8.1)
prior to injection of 1 mL of denatured/reduced lysozyme with various concentrations
(30, 40 and 50 mg/mL) . The sample was eluted using the same buffer and flow rate of 1
mL/min. Fractions of 1 mL were collected and concentrations of native protein were
determined using RPHPLC. The same procedure was followed for refolding of
denatured/reduced lysozyme after DTT removal.

4.3.7 Solubility Test
Samples of 40 mg/mL DTT-free lysozyme in 0.1 M Tris-base, 1 mM EDTA, 6 M urea
buffered at pH 8.1 were diluted using a 0.1 M Tris-base, 1 mM EDTA buffer pH
8.1containing urea and ʟ-arginine without redox couple. The urea and ʟ-arginine
concentrations were adjusted to result in a buffer identical to refolding buffer used during
on-column refolding experiments considering the dilution factor. The absence of redox
couple quenches the reaction at early intermediates [18]. DTT was removed for the same
reason to avoid the formation of native protein during dilution experiments. The initial
concentration of diluted sample was 8 mg/mL which was incubated overnight. The
aggregates were precipitated by centrifuge and the concentration of solubilized protein in
supernatant was measured by total protein assay.

4.3.8 Urea Injection
A sample of 6 M urea was prepared in a buffer similar to the refolding buffer
composition with the exception of urea. No urea was used in this buffer to avoid high
dilution factors during urea concentration measurements. 0.5 mL of this sample was
injected on the SEC column and eluted with 1 mL/min flow rate of the same buffer while
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collecting fractions of 1 mL. The experimental elution profile of urea was obtained by
measuring urea concentration in the samples using urea assay kit.

4.3.9 SMB-SEC Simulations
After determining the necessary model parameters, the SMB-SEC operational parameters
(i.e. external and internal flow rates and switching time) were selected using triangle
theory. Based on this theory, inequalities of (4-8a)(a-c) correspond to a design space
where complete separation can be achieved [20].
𝐾𝑒𝑞,𝑢𝑟𝑒𝑎 < 𝑚1 < ∞

(4-8a)

𝐾𝑒𝑞,𝑁 < 𝑚2 < 𝑚3 < 𝐾𝑒𝑞,𝑢𝑟𝑒𝑎

(4-8b)

−𝜀𝑝
< 𝑚4 < 𝐾𝑒𝑞,𝑢𝑟𝑒𝑎
(1 − 𝜀𝑝 )

(4-8c)

where 𝑚𝑗 is called flow rate ratio and defined as ratio of net liquid flow rate to net solid
phase flow rate in zone 𝑗 and 𝜀𝑝 is particle porosity. Particle porosity was measured
experimentally using acetone and thyroglobulin from bovine thyroid injections on single
column. Acetone and thyroglobulin from bovine thyroid elution volume to total column
volume ratio measures total porosity (𝜀) and void volume (𝜀𝑏 ) respectively and the
particle porosity is calculated as: 𝜀𝑝 =

𝜀−𝜀𝑏
1−𝜀𝑏

. Total porosity, void volume and particle

porosity were found to be 0.9, 0.34 and 0.8 respectively. The equilibrium constants for
native lysozyme and urea were found by least-squares fitting of the deviation of
measured concentration vs. calculated for native protein and urea when native lysozyme
and pure urea were injected on the single column. The fitted parameters are 0.9 for urea
and 0.44 for native lysozyme [17]. The liquid flow rate in each SMB-SEC zone is related
to phase ratio by the following
𝑄𝑗 =

𝑚𝑗 𝑉𝑐 (1 − 𝜀) + 𝑉𝑐 𝜀
𝑡𝑠

(4-9)

where 𝑡𝑠 is the switching time.
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In addition to the above criteria the flow rates must be within lowest and the highest flow
rate range which are considered 0.25 and 3 mL/min respectively. For the selected flow
rate range, Young and Wilson-Geankoplis correlations [6] were used to determine the
controlling mass transfer resistance by order of magnitude analysis which revealed the
pore resistance as the major resistance component. Since this value is independent of the
velocity the estimated model parameters are valid for the selected flow rate range. The
highest flow rate is determined based on maximum allowable pressure over the system
compatible with packing and column material. Table 4-1 reports the operational
parameters which were used during SMB-SEC simulations.
Table 4-1. SMB-SEC operational parameter selected based on triangle theory
𝑡𝑠

Phase
ratios

𝑄𝐷 =𝑄1

𝑄2

𝑄3

𝑄4 =𝑄𝑊

𝑄𝐸𝑥

𝑄𝐹

𝑄𝑅𝑎

(min) (mL/min) (mL/min) (mL/min) (mL/min) (mL/min) (mL/min) (mL/min)

𝑚1 =1.3
𝑚2 =0.6

2.7

2.72

1.66

1.96

1.21

1.04

0.30

0.74

3

2.39

1.47

1.74

1.08

0.92

0.26

0.66

3.3

2.17

1.34

1.58

0.98

0.84

0.24

0.64

𝑚3 =0.8
𝑚4 =0.3

The continuous and batch process performance indicators are defined as:
𝑅𝑏,𝑒𝑥𝑝 =

𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒
𝐿𝑉𝑝𝑢𝑙𝑠𝑒

𝑅𝑐,𝑝𝑟𝑒𝑑 =

(4-10a)

𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝑄𝑅𝑎
𝑄𝐹 𝐶𝑓,𝑈

(4-10b)

Where 𝑅𝑏 and 𝑅𝑐,𝑝𝑟𝑒𝑑 are experimental and predicted solubilized lysozyme recovery for
batch and continuous refolding respectively. 𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒 is sum of solubilized protein mass
collected in fractions, 𝑉𝑝𝑢𝑙𝑠𝑒 injection volume, 𝐿 lysozyme loading concentration and
𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
predicted average concentration of solubilized protein at cyclic steady state.
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𝑃𝑟𝑏,𝑒𝑥𝑝 =

𝑃𝑟𝑐,𝑝𝑟𝑒𝑑

𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒
𝑉𝐶 𝑡𝑒

(4-11a)

𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝑄𝑅𝑎
=
𝑁𝑡 𝑉𝐶

(4-11b)

where 𝑃𝑟𝑏,𝑒𝑥𝑝 , 𝑃𝑟𝑐,𝑝𝑟𝑒𝑑 , 𝑡𝑒 , 𝑉𝑐 , and 𝑁𝑡 are experimental and predicted volumetric
productivity for batch and continuous configurations, elution time of protein for batch
experiments, volume of the column and total number of columns used for SMB-SEC
respectively.
𝑃𝑐,𝑝𝑟𝑒𝑑

𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
= 𝐶𝑆𝑆
𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎 + 𝐶𝑢𝑟𝑒𝑎.𝑅𝑎

(4-12)

𝑃𝑐,𝑝𝑟𝑒𝑑 is the predicted product purity.
𝐵𝑐𝑏,𝑒𝑥𝑝 =

𝑄𝑏 𝑡𝑒
𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒

𝐵𝑐𝑐,𝑝𝑟𝑒𝑑 =

(4-13a)

𝑄𝐷
𝐶𝑆𝑆
𝐶𝑆𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎 𝑄𝑅𝑎

(4-13b)

where 𝐵𝑐𝑏,𝑒𝑥𝑝 and 𝐵𝑐𝑐,𝑝𝑟𝑒𝑑 are experimental and predicted buffer consumption and 𝑄𝑏 is
elution flow rate used for single column batch experiments.

4.4 Results and Discussions
4.4.1 Single-column Batch Refolding
When 1 mL of 30, 40 and 50 mg/mL of denatured/reduced lysozyme was refolded on
SEC, although no protein signal was observed for aggregates, the refolding yield values
(70, 50 and 40%) suggested formation of insoluble aggregates and in-column
precipitation of these species. In order to decide whether aggregation is kinetically
controlled by competition of refolding and aggregation or if a critical concentration is
required,

two

models

were

examined
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to

predict

the

results

of

lysozyme

refolding/aggregation on SEC for the concentration ranges used in this work as well as
our previous work (described in section 4.2.3) [17] . Figure 4-3 shows that the
assumption that thermodynamic condition for aggregation formation is always satisfied
does not provide a satisfactory agreement between experimental and predicted results.

Figure 4-3. Experimental vs predicted elution profile of native refolded lysozyme
assuming thermodynamic condition for aggregation formation is always satisfied.
Since the competing reaction rates are dependent on local concentration of protein the
experimental injection profile of the protein was measured and used instead of commonly
used simplified rectangular injection profile to provide a more accurate representation of
the local protein concentrations. As shown in Figure 4-4 Gaussian type functions provide
a good representation of the injection profiles of the protein in the system under study. It
is evident from the same figure that the actual injection profile significantly deviates from
the rectangular assumption. Using the experimental injection profile however, did not
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change previously estimated model parameters namely mass transfer and equilibrium
constants for kinetic species (data not shown).

Figure 4-4. Experimental injection profile of lysozyme and its comparison with
simplified rectangular injection profile.
The experimental injection profile was then introduced to the model. Nevertheless, the
model prediction was not satisfactory (as shown on Figure 4-3) suggesting that the model
is not adequate and thermodynamic condition for aggregation is not satisfied for the
whole concentration range. In other words, aggregation should be only introduced to the
model when the local protein concentration exceeds a critical concentration (i.e.
solubility of early intermediate species). As illustrated in Figure 4-5 the modified model
considering a critical concentration and experimental injection profile of the protein
provides an improved agreement between experimental and predicted results. The two
fitted parameters namely aggregation kinetic constant (𝑘𝑎 ) and early intermediate
solubility (𝐶𝑠 ) however were found to be correlated and multiple solutions were obtained
for minimization problem. Consequently, the solubility parameter was measured
experimentally as described in section 4.3.7. The experimental and fitted parameters were
4.4±0.9 mg/mL and 0.05±2.8 x 10-5 mL/mg min respectively.
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Figure 4-5. Experimental vs predicted elution profile of native refolded lysozyme using
both simplified rectangular and experimental injection profiles.

4.4.2 Single-column Batch Refolding of DTT-free Lysozyme
The apparent refolding kinetic of DTT-free lysozyme found to be equal to lysozyme
refolding with carry-over of DTT within experimental error. It can be seen in Figure 4-6
that 𝑘𝑎𝑝𝑝 =0.08 min-1 adequately predicts the result of DTT-free lysozyme refolding on
SEC at loading concentrations of ~5 and 10 mg/mL and 1 mL injection volume. This is
because the refolding kinetic constant with DTT carry-over was measured for a system
with high dilution factor (~50 times) and the carry-over of reduced DTT was
insignificant.
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Figure 4-6. Experimental vs predicted elution profile of refolded native lysozyme for
DTT- free lysozyme loading concentrations of 5 mg/mL and 10 mg/mL; DTT-free
lysozyme obtained from desalting column was pooled, concentrated and injected on SEC.

4.4.3 Model Parameters for Urea
The

experimental

mass

transfer

and

equilibrium

constants

for

urea

(𝑘𝑜𝑣,𝑢𝑟𝑒𝑎 and 𝐾𝑒𝑞,𝑢𝑟𝑒𝑎 ) were found to be 51.97±0.02 min-1 and 0.9±0.1. Figure 4-7
illustrates the experimental versus predicted urea concentration at the column outlet using
experimentally measured mass transfer parameters as well as parameters calculated by
available correlations. It was observed that correlations do not provide an accurate
prediction of urea elution profile. For this reason, the fitted values of mass transfer
parameters were applied to predict the local concentrations of urea through the SMB-SEC
columns and at the raffinate stream.
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Figure 4-7. Experimental vs predicted elution profile of urea; predicted with the
coefficients taken from correlations and coefficients taken from independent experiments.

4.4.4 SMB-SEC Model Validation
Park et al. [7] have studied the refolding of DTT-free lysozyme (1.78 mg/mL) in a 1-1-11 four zone SMB-SEC. The model developed in the current work, was initially tested
against their experimental results and native protein concentration and refolding yield at
product outlet was predicted with 9.3% and 5.5% relative error respectively. Although,
the discrepancy between model prediction and existing experimental results is not
significant, the model must be tested under various operation conditions such as loading
concentrations for further validation.
It can be seen from Figure 4-8 that for the configuration used in this work, there is an
overlap between urea and protein concentrations. The overlapping area corresponds to the
length of two columns in SMB-SEC. This observation suggest that more experimentation
may be required to relate the model parameters namely apparent refolding kinetic
constant, solubility of early intermediates and aggregation constant to local concentration
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of urea in order to account for the effect of dynamic chemical environment on these
parameters [21].

Figure 4-8. Mid cycle concentration profiles of urea and early intermediates through
SMB-SEC columns for the operating condition reported in Table 4-1 and 10 mg/mL
DTT-free lysozyme loading concentration (The number of switching time was fixed at 30
in order to assure steady state operation); (A) ts =2.7 min, (B) ts =3 min and (C) ts =3.3
min.
Urea has demonstrated both denaturing and protective osmolyte properties [22,23]. For
example, no native conformation has been observed for lysozyme at urea concentrations
above 5 M [24] whereas urea concentrations under 3 M seem to increase the stability of
the

collapsed-globular

state

of

poly

(N-isopropylacrylamide)

and

shift

the

unfolded/folded equilibrium towards folded conformations [22]. Under the current
operating conditions, as can be seen in Figure 8, urea concentration varies along the
columns between no excess urea compared to the refolding buffer (total urea
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concentration of 2M) and about 50% of the urea present in the feed (total urea
concentration of about 5M). Since the model parameters were measured using the
refolding buffer during single-column experiments with much higher dilution factor, the
developed model with constant kinetic and thermodynamic parameters may over-predict
the native protein concentration at SMB-SEC product outlet as it disregards lower
refolding kinetics and equilibrium in higher urea concentrations. Over-prediction of the
native protein concentration results in under-prediction of protein aggregation. However,
this error may be balanced by higher solubility of early intermediates and reduced
aggregation in higher urea concentrations.
On the other hand, simulations for the above operating conditions showed no urea in the
raffinate stream, indicating the refolding reaction will continue off-column with the same
kinetics as single column experiments to recover the desired product. Therefore in this
work, process performance indicators were defined based on total solubilized protein
rather than native protein. And accordingly, it is suggested that the model is tested against
experiments for total solubilized protein. It should be noted that in the presence of ʟ arginine, aggregates precipitate and solubilized protein only include early intermediates
and native protein conformations.

4.4.5 SMB-SEC Performance
Based on above discussion, the model with constant parameters was used to study the
effect of operating parameters on process performance indicators namely solubilized
protein recovery and productivity, product purity at the raffinate outlet and buffer
consumption . Table 4-2 shows the results of SMB-SEC simulations at operating
condition corresponding to switching time of 3 min in Table 4-1 for feed concentrations
of 5-40 mg/mL. The corresponding SEC experimental results are also reported when data
was available from experiments.
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Table 4-2. SMB-SEC simulations feed concentrations of 5-40 mg/mL, switching time of
3 min and available corresponding SEC experimental results. SEC results are reported for
elution flow rate of 1 mL/min and injection volume of 0.5 mL.
𝐶𝑓,𝑈

𝑅𝑐,𝑝𝑟𝑒𝑑

𝑃𝑟𝑐,𝑝𝑟𝑒𝑑

𝐵𝑐𝑐,𝑝𝑟𝑒𝑑

𝑅𝑏,𝑒𝑥𝑝

𝑃𝑟𝑏,𝑒𝑥𝑝

𝐵𝑐𝑏,𝑒𝑥𝑝

(mg/mL)

(-)

(mg/mL h)

(mL/mg)

(-)

(mg/mL h)

(mL/mg)

5

1.0

1.6

1.9

1.0

0.1

13.6

10

1.0

3.0

1.0

1.0

0.2

6.8

15

1.0

4.8

0.6

-

-

-

20

0.8

5.4

0.5

1.0

0.3

3.4

40

0.5

6.0

0.5

0.9

0.6

1.9

It can be seen that, although productivity increases and buffer consumption is reduced at
higher feed concentrations, the recovery decreases for concentrations equal and above 20
mg/mL showing aggregation formation. As expected the productivity and buffer
consumption in SMB-SEC were significantly improved compared to SEC. The buffer
consumption can be further reduced by using a closed loop configuration and buffer
recycling. For oxidative refolding however, the redox couple ratio might change over
time resulting in non-optimal buffer composition. It was previously demonstrated that
lysozyme refolds at higher pH values closer to its isoelectric point without the need for
redox couple while aggregation was suppressed due to the presence of ʟ -arginine and the
refolding yield did not show a significant change [18]. Based on the characteristics of the
protein under study oxidative refolding without the need for a redox couple might offer
advantages in terms of chemical cost, buffer preparation and storage but further kinetic
studies are required to compare refolding with and without a redox couple. As mentioned
100% purity was estimated for SMB-SEC as predictions showed no urea at the raffinate
stream.
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In order to explore the effect of switching time, the simulations were also carried out for
the above feed concentration range and operating conditions corresponding to switching
times of 2.7 and 3.3 min. As shown in Table 4-3, in the studied concentration range
switching time of 2.7 min resulted in highest productivity compared to switching times of
3 and 3.3 min and up to 50% improvement was observed for loading concentration of 5
mg/mL, while recovery and buffer consumption did not vary significantly by change of
the switching time. The same trend was observed for switching times of 2.7 and 3.3 min
in terms of recovery drop for concentrations equal and above 20 mg/mL as switching
time of 3 min.
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Table 4-3. SMB-SEC productivity simulations for feed concentrations of 5-40 mg/mL
and various operation conditions corresponding to three different switching times used in
this work.
𝐶𝑓,𝑈

𝑡𝑠

𝑃𝑟𝑐,𝑝𝑟𝑒𝑑

(mg/mL)

(min)

(mg/mL h)

5

2.7

1.8

10

2.7

3.6

15

2.7

5.4

20

2.7

6.0

40

2.7

7.2

5

3

1.6

10

3

3.0

15

3

4.8

20

3

5.4

40

3

6.0

5

3.3

1.2

10

3.3

3.0

15

3.3

4.2

20

3.3

5.4

40

3.3

6.0
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4.5 Conclusions
This work illustrates important considerations for utilizing single-column data towards
design/operation of an SMB process. Our findings showed: 1) at higher local protein
concentrations aggregation occurs when local protein concentration exceeds a critical
concentration (i.e. solubility of early intermediates); 2) if DTT is to be removed from
denatured/reduced lysozyme to avoid further complexity in developing a model and the
adverse effect of this reagent on refolding kinetics, the single-column parameters
obtained with DTT carry-over are still valid provided they were obtained for a column
with high dilution factor; 3) a model with constant kinetic and thermodynamic parameters
may not result in accurate prediction of native protein; however, 4) under the operation
condition studied, the refolding reaction will continue off-column as predictions showed
no urea in the raffinate stream ; and 5) it is suggested that the model is tested against total
solubilized protein rather than native protein and the process performance indicators are
defined accordingly; finally 6) the prediction of SMB-SEC performance for loading
concentrations of 5-40 mg/mL, using the model with constant parameters, showed that
increasing the concentration increases the productivity and decreases the buffer
consumption however at concentrations equal to and higher than 20 mg/mL aggregates
are formed and precipitate in the column. The operating condition corresponding to
lowest switching time resulted in highest productivity and no significant effect on
recovery and buffer consumption.
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5 Summary and Future Work Recommendations
In spite of the advances made to date for expression of protein-therapeutics using E. coli
host [1], the existing technologies to recover active and high-purity product still suffer
from low refolding yields, volumetric productivities and high buffer consumption for
commercial scale production which impose constraints in terms of time and cost [2]. This
research work focused on various process development and optimization strategies to
improve on above mentioned process performance indicators in size exclusion
chromatography which has been extensively used at lab scale for protein refolding
purpose. The outcome of this research is meant to be general, with broad application for
cost effective high-throughput inclusion-body-based protein production.
Chapter 2 of this thesis presents a multivariable investigation of various parameters of the
refolding buffer namely buffer pH, sodium chloride and ʟ-arginine concentrations. It was
illustrated that the benefit of using ʟ-arginine is twofold as, in addition to preventing
aggregation of lysozyme for loading concentrations of up to 40 mg/mL, it introduced the
possibility of adjusting the buffer redox potential by controlling the pH to assist
reformation of disulfide bridges without the need for costly redox couple chemicals. ʟarginine also reduced the pore accessibility for small molecules of urea and DTT at
higher protein concentrations indicating gradual removal of these agents which may be an
additional mechanism by which this additive prevents aggregation in size exclusion
chromatography. Further experimentation is however required to test these observations
for other protein systems.
In Chapter 3, various methods were introduced for high-throughput measurements of
mass transfer parameters and distribution coefficients of refolding kinetic species by
single-column experiments in order to establish an experimentally-verified mathematical
model. These methods included non-reactive native protein, model protein compounds
and equilibrium experiments to extract characteristic information for native protein, early
collapsed intermediates and native-like intermediates respectively. Although this was
only demonstrated for the model protein (lysozyme), the same methods can be used for
other oxidative and non-oxidative refolding cases. It was also demonstrated that the
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above mentioned parameters from size exclusion chromatography may be improperly
estimated due to non-specific interaction of species with the chromatography gel even
when ʟ-arginine was used; which is commonly suggested for reduced protein interaction
with surfaces and increased recovery in various chromatography methods [3–5]. In
addition, the importance of kinetic studies in deciding on an appropriate refolding
additive was discussed. In this work, ʟ-arginine additive was found to prevent
aggregation without compromising the speed of lysozyme refolding.
Finally, investigations on the suitability of utilizing single-column data towards
prediction of the behavior of the protein in multi-column continuous simulated moving
bed size exclusion chromatography (SMB-SEC) and design/operation of a continuous
process were carried out; presented in Chapter 4 of this thesis. The SMB-SEC technology
offers many advantages compared to single-column processing, including increased
productivity per unit mass of solid phase, lower solvent consumption, and less diluted
products all of which makes it an attractive technology for future industrial applications.
Since operation of a SMB-SEC unit includes more degrees of freedom compared to
single-column operation, a systematic optimization is essential to obtain the operating
parameter setting (s) that result in optimum process performance indicators. Accordingly,
a robust mathematical model is a necessary tool for successful operation of a SMB-SEC.
Therefore, the model that was developed in Chapter 3 was modified to extend its
applicability for SMB-SEC. The prediction of unfolded protein and urea concentrations
through a SMB-SEC showed lower dilution factors compared to single-column operation
in this work. As a lower dilution factor results in higher local protein concentrations,
protein aggregation was introduced into the model by introduction of a critical
concentration (i.e. solubility of early intermediates) above which aggregates are formed
with second-order rate kinetics of aggregation. Lower dilution factor also translates to a
higher denaturant local concentration, influencing measured kinetic and thermodynamic
parameters by single-column experiments.
Therefore, a model with constant kinetic and thermodynamic parameters may not result
in accurate prediction of native to early intermediate protein ratio and an under-prediction
of total solubilized protein concentration at the product line. However, if under various
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operation settings no or very low concentration of denaturant exist in the product line, as
it was the case in this work based on simulations, the refolding reaction will continue offcolumn to recover protein as functional native protein. Consequently, the process
performance indicators were defined based on total solubilized protein at the product
outlet (early intermediates and native protein). As a result the model with constant kinetic
and thermodynamic parameters can be used to predict the solubilized protein recovery
and find the operational space that meets an appropriate criterion for recovery where incolumn aggregation and precipitation is mainly prevented and productivity and buffer
consumption criteria are optimized. Experimentation on SMB-SEC systems is still
required in order to evaluate the validity of this approach under various operating
conditions.
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Appendices
Appendix A: MATLAB Codes
A.1 Parameter fitting for model without aggregation
clear all
clc
format short e
x0=0.1 ;
% initial guess-refolding reaction rate constant (min-1)
lb=0; % lower bound
ub=1; % upper bound
options = optimset('Display','iter');
[x,fval] = fmincon(@functioncal,x0,[],[],[],[],lb,ub,[],options);
% Returns the value of the objective function functioncal at the
solution x
function f=functioncal(x)
global
global
global
global

NPLATE
N
CfI
tpulse

%---------------------------------------------------------------------NPLATE = 100; % Number of plates
N = 4 * NPLATE; % Number of unknowns
%---------------------------------------------------------------------% transferring experimental data
CexpN=[0.00 0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
90

0.01
0.03
0.06
0.09
0.08
0.10
0.13
0.19
0.20
0.25
0.27
0.31
0.35
0.41
0.42
0.45
0.34
0.19
0.15
0.08
0.08
0.08
0.06
0.07
0.05
0.06
0.07
0.05
0.03
0.05
0.05
0.03
0.01
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
];

0.00
0.02
0.07
0.12
0.17
0.22
0.27
0.33
0.45
0.51
0.65
0.66
0.73
0.82
0.88
0.90
0.77
0.49
0.36
0.26
0.22
0.17
0.19
0.15
0.14
0.12
0.10
0.09
0.08
0.07
0.05
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.00
0.00
0.05
0.09
0.08
0.13
0.17
0.20
0.26
0.35
0.37
0.41
0.43
0.47
0.49
0.51
0.48
0.37
0.23
0.15
0.12
0.09
0.09
0.07
0.06
0.03
0.02
0.02
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.01
0.02
0.02
0.00
0.00
0.06
0.19
0.23
0.35
0.44
0.53
0.62
0.68
0.74
0.76
0.78
0.70
0.57
0.44
0.33
0.23
0.24
0.22
0.17
0.14
0.15
0.14
0.10
0.10
0.09
0.08
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

%---------------------------------------------------------------------%ODE integration
t0 = 0;
tf= 60;
y0 = zeros(N,1);
tspan= linspace (t0,tf,61);
f = 0;
%------------------------------91

CfIm = [5 10 10 20]; % loading concentration (mg cm-3)
tpulsem = [1 1 0.5 0.5]; % Injection time (min)
for j=1:4
CfI = CfIm (j);
tpulse = tpulsem (j);
[T, Y]=ode15s(@(t,y)elution_profile(t,y,x),tspan,y0);
%---------------------------------------------------------------------% calculating objective function
Cexp= CexpN (:,j);
for i=1:length(T)
f=f+(Y(i,3*N/4)-Cexp(i))^2 ;
end
end

function dydt = elution_profile(t, y, x)
global
global
global
global
%

NPLATE
N
CfI
tpulse

--------------- pre-allocating the variables

L = 27; % Column length (cm)
h = L / (NPLATE - 1); % Computing the step size
AREA = 2; % Column cross-section (cm2)
E = 0.34; % Bed void volume fraction (-)
Q = 1; % Flow rate (mL/min)
U = Q / (E * AREA); % Velocity (cm min-1)
P = (1 - E) / E; % Phase ratio
DL = 10 * U * 17e-4 * E; % Dispersion coefficient (cm2 min-1)
KsecN = 0.44; % Native protein distribution coefficient (-)
KsecI = 0.08; % Early intermediate protein distribution coefficient (-)
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KovI = 2.69; % Early intermediate overal mass transfer coefficient
(min-1)
KovN = 17.29; % Native protein overal mass transfer coefficient (min-1)
Krxn = x(1,1); % Refolding reaction rate constant (min-1)
%---------------------------------------------------------------------%Constants used in function
B1 = U / (2* h);
C1 = DL / (h ^2);
B2= U/ (12 * h);
C2=DL / (12 * (h ^2));
dydt = zeros(N,1);
KZF = lt(t, tpulse);
CfN = 0;
%------------------------------------------------------------------------%
Defining the ODEs

dydt(1) = C1 * ( KZF * CfI - 2 * y(1) + y(2)) - B1 * (-KZF * CfI +
y(2)) - P * KovI * (KsecI * y(1) - y(N/4+1)) -Krxn* y(1);

dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1);

dydt(N/2+1) = C1 * (KZF * CfN - 2 * y(N/2+1) + y(N/2+2)) - B1 * (- KZF
* CfN + y(N/2+2))- P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn *
y(1);

dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn *
y(N/4+1);

dydt(2) = C2 * ( - KZF * CfI + 16 * y(1) - 30 * y(2) + 16 * y(3) y(4)) - B2 * (KZF * CfI - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI *
(KsecI * y(2) - y(N/4+2)) - Krxn * y(2);

dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2);

dydt(N/2+2) = C2 * (-KZF * CfN + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 *
y(N/2+3) - y(N/2+4)) - B2 * (KZF * CfN - 8 * y(N/2+1) + 8 * y(N/2+3) y(N/2+4))- P * KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2);
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dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn *
y(N/4+2);

for I=3:N/4-2
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I);

dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I);

dydt(N/2+I) = C2 * (- y (N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) +
16 * y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8
* y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I))
+ Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) -y(3*N/4+I)) + Krxn *
y(N/4+I);
end

dydt(N/4-1) = C2 * (- y (N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 *
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4))
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1);

dydt(N/2-1) = KovI *( KsecI * y(N/4-1)-y(N/2-1)) - Krxn * y(N/2-1);

dydt(3*N/4-1) = C2 * (- y (3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1)
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 *
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn
* y(N/4-1);

dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1);

dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) + y(N/4)) - B1 * (- y(N/4-1) +
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4);

dydt(N/2) = KovI *( KsecI * y(N/4)-y(N/2))- Krxn * y(N/2);
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dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn *
y(N/4);
dydt(N) = KovN *( KsecN * y(3*N/4) -y(N)) + Krxn * y(N/2);

A. 2 Parameter fitting for model with aggregation and Gaussian injection
profile
clear all
clc
format short e
x0=0.1 ;

% initial guess-aggregation reaction rate constant (min-1)

options = optimset('Display','iter');
[x,fval] = fminsearch(@functioncal,x0,options);
function f=functioncal(x)
global NPLATE
global N
global a
%-------------------------------------------------------------------------------------------------------NPLATE = 100;
N = 4 * NPLATE;

% Number of plates
% Number of unknowns

%--------------------------------------------------------------------% transferring experimental data
CexpN=[0.00 0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.00
0.00
0.01
0.02
0.01
0.00
0.03
0.02
0.00
0.02
0.04
95

0.01
0.07
0.09
0.10
0.19
0.26
0.36
0.40
0.57
0.68
0.80
0.92
1.11
1.33
1.29
1.06
0.77
0.73
0.62
0.53
0.42
0.46
0.42
0.33
0.36
0.20
0.17
0.10
0.05
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
];

0.01
0.04
0.07
0.11
0.18
0.26
0.37
0.47
0.58
0.64
0.78
0.86
0.95
0.99
0.80
0.59
0.40
0.28
0.18
0.17
0.13
0.11
0.10
0.07
0.05
0.05
0.04
0.03
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.06
0.09
0.08
0.10
0.13
0.19
0.20
0.25
0.27
0.31
0.35
0.41
0.42
0.45
0.34
0.19
0.15
0.08
0.08
0.08
0.06
0.07
0.05
0.06
0.07
0.05
0.03
0.05
0.05
0.03
0.01
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00

0.07
0.12
0.17
0.22
0.27
0.33
0.45
0.51
0.65
0.66
0.73
0.82
0.88
0.90
0.77
0.49
0.36
0.26
0.22
0.17
0.19
0.15
0.14
0.12
0.10
0.09
0.08
0.07
0.05
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.05
0.09
0.08
0.13
0.17
0.20
0.26
0.35
0.37
0.41
0.43
0.47
0.49
0.51
0.48
0.37
0.23
0.15
0.12
0.09
0.09
0.07
0.06
0.03
0.02
0.02
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.02
0.00
0.00
0.06
0.19
0.23
0.35
0.44
0.53
0.62
0.68
0.74
0.76
0.78
0.70
0.57
0.44
0.33
0.23
0.24
0.22
0.17
0.14
0.15
0.14
0.10
0.10
0.09
0.08
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.04
0.09
0.09
0.13
0.20
0.22
0.41
0.41
0.54
0.67
0.89
0.95
0.99
1.22
1.25
1.22
1.03
0.86
0.70
0.59
0.48
0.46
0.39
0.35
0.33
0.28
0.26
0.26
0.22
0.20
0.15
0.13
0.11
0.07
0.15
0.13
0.11
0.07
0.00
0.00
0.00

%--------------------------------------------------------------------%ODE integration
t0 = 0;
tf= 60;
y0 = zeros(N,1);
tspan= linspace (t0,tf,61);
f = 0;
%------------------------------am = [26.56 13.28 3.36 6.59 3.36 6.59 16.6];
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for j=1:7
a = am (j);
[T, Y]=ode15s(@(t,y)elution_profile(t,y,x),tspan,y0);
%---------------------------------------------------------------------% calculating objective function
Cexp= CexpN (:,j);
for i=1:length(T)
f=f+(Y(i,3*N/4)-Cexp(i))^2 ;
end
end
function dydt = elution_profile(t, y, x)
global NPLATE
global N
global a

%

--------------- pre-allocating the variables

L = 27; % Column length (cm)
h = L / (NPLATE - 1); % Computing the step size
AREA = 2; % Column cross-section (cm2)
E = 0.34; % Bed void volume fraction (-)
Q = 1; % Flow rate (mL/min)
U = Q / (E * AREA); % Velocity (cm min-1)
P = (1 - E) / E; % Phase ratio
DL = 10 * U * 17e-4 * E; % Dispersion coefficient (cm2 min-1)
KsecN = 0.44; % Native protein distribution coefficient (-)
KsecI = 0.08; % Early intermediate protein distribution coefficient (-)
KovI = 2.69; % Early intermediate overal mass transfer coefficient
(min-1)
KovN = 17.29; % Native protein overal mass transfer coefficient (min-1)
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Krxn = 0.08; % Refolding reaction rate constant (min-1)
kag = x(1,1); % Aggregation reaction rate constant (mLmin-1mg-1)
ys = 4.4; % Early intermediate solubility (mgmL-1)
%---------------------------------------------------------------------% Constants used in function
B1 = U / (2* h);
C1 = DL / (h ^2);
B2= U/ (12 * h);
C2=DL / (12 * (h ^2));
dydt = zeros(N,1);
CfN = 0;
% Gaussian function and smooth step function
b = 1.5;
c = 0.58;
k = 100;
KZF = a * exp(-0.5*((t-b)/c)^2);
%---------------------------------------------------------------------%
Defining the ODEs

dydt(1) = C1 * ( KZF - 2 * y(1) + y(2)) - B1 * (-KZF + y(2)) - P *
KovI * (KsecI * y(1) - y(N/4+1)) -Krxn* y(1)- 2* kag * (1/(1+exp(2*k*(y(1)-ys))))*y(1)*y(1);

dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1)-2 *
(1/(1+exp(-2*k*(y(N/4+1)-ys))))* kag *(y(N/4+1))*(y(N/4+1));

dydt(N/2+1) = C1 * (KZF * CfN - 2 * y(N/2+1) + y(N/2+2)) - B1 * (- KZF
* CfN + y(N/2+2))- P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn *
y(1);

dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn *
y(N/4+1);

dydt(2) = C2 * ( - KZF + 16 * y(1) - 30 * y(2) + 16 * y(3) - y(4)) - B2
* (KZF - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI * (KsecI * y(2) y(N/4+2)) - Krxn * y(2)-2* kag * (1/(1+exp(-2*k*(y(2)ys))))*(y(2))*(y(2));

dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2)-2 *
(1/(1+exp(-2*k*(y(N/4+2)-ys))))* kag *(y(N/4+2))*(y(N/4+2));
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dydt(N/2+2) = C2 * (-KZF * CfN + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 *
y(N/2+3) - y(N/2+4)) - B2 * (KZF * CfN - 8 * y(N/2+1) + 8 * y(N/2+3) y(N/2+4))- P * KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2);

dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn *
y(N/4+2);

for I=3:N/4-2
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)ys))))* kag *(y(I))*(y(I));

dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 *
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* kag *(y(N/4+I))*(y(N/4+I));

dydt(N/2+I) = C2 * (- y (N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) +
16 * y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8
* y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I))
+ Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) -y(3*N/4+I)) + Krxn *
y(N/4+I);
end

dydt(N/4-1) = C2 * (- y (N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 *
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4))
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1)-2*
(1/(1+exp(-2*k*(y(N/4-1)-ys))))* kag *(y(N/4-1))*(y(N/4-1));

dydt(N/2-1) = KovI *( KsecI * y(N/4-1)-y(N/2-1)) - Krxn * y(N/2-1)-2 *
(1/(1+exp(-2*k*(y(N/2-1)-ys))))* kag *(y(N/2-1))*(y(N/2-1));

dydt(3*N/4-1) = C2 * (- y (3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1)
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 *
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn
* y(N/4-1);

dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1);
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dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) + y(N/4)) - B1 * (- y(N/4-1) +
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4)- 2 *
(1/(1+exp(-2*k*(y(N/4)-ys))))* kag *(y(N/4))*(y(N/4));

dydt(N/2) = KovI *( KsecI * y(N/4)-y(N/2))- Krxn * y(N/2)-2 *
(1/(1+exp(-2*k*(y(N/2)-ys))))* kag *(y(N/2))*(y(N/2));

dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn *
y(N/4);
dydt(N) = KovN *( KsecN * y(3*N/4) -y(N)) + Krxn * y(N/2);

A.3 SMB-SEC
clear all
clc
format long
global NP
global n1
global n2
global n3
global N
global QF
global
global
global
global

QD
Q2
Q3
Q4

global CfI
global CfN
NP = 50; % Number of plates for each column
n1
n2
n3
n4

=
=
=
=

2;
2;
2;
2;

%Number
%Number
%Number
%Number

of
of
of
of

columns
columns
columns
columns

in
in
in
in

section
section
section
section

1
2
3
4

Nt = n1+n2+n3+n4; %Total number of columns
Vc = 6; % Volume of each column (mL)
N = 4 * NP * Nt; % Number of unknowns
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QD = 2.4; % Eluent flow rate (mL min-1)
QF = 0.26; % Feed flow rate (mL min-1)
QRa = 0.66; % Raffinate flow rate (mL min-1)
Q4 = 1.1; % Internal flow rate zone 4 and waste
Q3 = Q4 + QRa; % Internal flow rate zone 3
Q2 = Q4+QRa-QF; %Internal flow rate zone 2
CfI = 30; % Feed concentration mg mL-1
CfN = 0;
Nswitch = 30; % Number of switch times
%---------------------------------------------------------------------% ODE integration
y0 = zeros(N,1);
y1 = zeros(1,NP);
y2 = zeros(1,NP);
y3 = zeros(1,NP);
y4 = zeros(1,NP);
RaI =zeros (Nswitch,1);
RaN = zeros (Nswitch,1);
ExI = zeros (Nswitch,1);
ExN = zeros (Nswitch,1);
RecI = zeros (Nswitch,1);
RecN = zeros (Nswitch,1);
PrN = zeros (Nswitch,1);
BcN = zeros (Nswitch,1);
fid1 = fopen('profileI.txt','w');
fprintf(fid1,'%6s %6s %12s
%12s\r\n','k','j','Location','Intermediate');
fid2 = fopen('profileN.txt','w');
fprintf(fid2,'%6s %6s %12s %12s\r\n','k','j','Location','Native');
for k=1:Nswitch
t0 = 0;
ts= 3; % Switch time
tint = 101;
tspan= linspace(t0,ts,tint);
[T, Y] = ode15s(@SMB_Simulation, tspan, y0);

Yout = zeros (length(T),Nswitch*N);
Yout(:,(k-1)*N+1:k*N)= Y(:,1:N);

if (mod(k,8)== 0)
for j=1:10:tint %beginning, mid and end of each cycle
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for I=NP/10:NP/10:N/4; %every 5plate

fprintf(fid1,'%12d %12d %12d %4.2f\r\n',k,j,I,Yout(j, (k-1)*N +I)); % I
concentration profile along the SMB columns
fprintf(fid2,'%12d %12d %12d %4.2f\r\n',k,j,I,Yout(j, (k-1)*N +N/2+I));
% N concentration profile along the SMB columns
end
end
end

RaI(k,1) = (trapz(T,Yout(:,(k-1)* N + (n1+n2+n3)* NP)))/ ts; % Cyclic
steady state concentration of I in Raffinate stream
RaN(k,1) = (trapz(T,Yout(:,(k-1)* N + N/2+(n1+n2+n3)* NP)))/ ts;%
Cyclic steady state concentration of N in Raffinate stream
ExI(k,1) = (trapz(T,Yout(:,(k-1)* N+ n1* NP)))/ ts ;% Cyclic steady
state concentration of I in Extract stream
ExN(k,1) = (trapz(T,Yout(:,(k-1)* N+ N/2+n1* NP)))/ ts;% Cyclic steady
state concentration of N in Extract stream
WI(k,1) = (trapz(T,Yout(:,(k-1)* N + (n1+n2+n3+n4)* NP)))/ ts;% Cyclic
steady state concentration of I in Waste stream
WN(k,1) = (trapz(T,Yout(:,(k-1)* N + N/2+(n1+n2+n3+n4)* NP)))/ ts;%
Cyclic steady state concentration of N in Waste stream

RecN(k,1)=RaN(k,1)*(Q3-Q4)/(QF*CfI) ; %Recovery N
RecI(k,1)=RaI(k,1)*(Q3-Q4)/(QF*CfI);%Recovery I
PrN(k,1)= (RaN(k,1)+RaI(k,1))*(Q3-Q4)/(Nt*Vc);% Volumetric productivity
in terms of solubilized protein (mg mL-1 min-1)
BcN(k,1)= QD/ ((RaN(k,1)+RaI(k,1))*(Q3-Q4));% Buffer consumption (mL
mg-1)

for I=1:NP % store column 1 information @ tint
y1(1,I)
y2(1,I)
y3(1,I)
y4(1,I)

=
=
=
=

Y(tint,I);
Y(tint,N/4+I);
Y(tint,N/2+I);
Y(tint,3*N/4+I);

end
for J=0:Nt-2 % switching column in direction of solid movement
for I=1:NP
Y(tint,I+J*NP) = Y(tint,I+(J+1)*NP);
Y(tint,N/4+I+J*NP)= Y(tint,N/4+I+(J+1)*NP);
Y(tint,N/2+I+J*NP)= Y(tint, N/2+I+(J+1)*NP);
Y(tint,3*N/4+I+J*NP)= Y(tint,3*N/4+I+(J+1)*NP);
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end
end
for I=1:NP
Y(tint,N/4-NP+I)= y1(1,I);
Y(tint,N/2-NP+I)= y2(1,I);
Y(tint,3*N/4-NP+I)= y3(1,I);
Y(tint,N-NP+I)= y4(1,I);
end
y0 = Y(tint,:).'; % Initial condition for new cycle

end
fclose(fid1);
fclose(fid2);

function dydt = SMB_Simulation(t,y)
global NP
global n1
global n2
global n3
global N
global QF
global
global
global
global

QD
Q2
Q3
Q4

global CfI
global CfN

%
--------------- pre-allocating the variables
AREA = 0.78; % Column cross section (cm2)
E = 0.34; % Bed void volume fraction (-)
L = 8; % Column length (cm)
KsecI = 0.08; % Equilibrium constant for Intermediate protein (-)
KsecN = 0.44; % Equilibrium constant for Native protein (-)
KovI = 2.69; % Mass transfer coefficient for Intermediate protein (min1)
KovN = 17.29; % Mass transfer coefficient for Native protein (min-1)
Krxn = 0.08; % Refolding reaction rate constant (min-1)
Kag = 0.08; % Aggregation reaction rate constant (min-1)
ys = 4.4; % Early intermediate solubility (mg mL-1)
k = 1000;
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h =L /(NP - 1); % Axial step size
P = (1 - E) / E; % Phase ratio
%---------------------------------------------------------------------PP = n1 * NP;
PQ = PP + n2 * NP;
PQR =PQ + n3 * NP;
%---------------------------------------------------------------------dydt = zeros(N,1);
%---------------------------------------------------------------------% Stage 1 &2 -------------Eluent point
U = QD/(AREA * E);
B1 = U/(2 * h);
Dl = 10 * U * 17e-4 * E;
C1 = Dl/(h ^ 2);
B2=U/(12 * h);
C2=Dl/(12 *h ^2);

% Central second order
dydt(1) = C1 * (0 - 2 * y(1) + y(2)) - B1 * (-0 + y(2)) - P * KovI *
(KsecI * y(1) - y(N/4+1)) - Krxn * y(1)- 2* Kag * (1/(1+exp(2*k*(y(1)-ys))))*y(1)*y(1);
% I liquid

dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1)-2 *
(1/(1+exp(-2*k*(y(N/4+1)-ys))))* Kag *(y(N/4+1))*(y(N/4+1));
% I
solid

dydt(N/2+1) = C1 * (0 - 2 * y(N/2+1) + y(N/2+2)) - B1 * (- 0 +
y(N/2+2)) - P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * y(1);

dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn *
y(N/4+1);
% Central fourth order
dydt(2) = C2 * ( - 0 + 16 * y(1) - 30 * y(2) + 16 * y(3) - y(4)) - B2 *
(0 - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI * (KsecI * y(2) - y(N/4+2))
- Krxn * y(2)-2* Kag * (1/(1+exp(-2*k*(y(2)-ys))))*(y(2))*(y(2));

dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2)-2 *
(1/(1+exp(-2*k*(y(N/4+2)-ys))))* Kag *(y(N/4+2))*(y(N/4+2));
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dydt(N/2+2) = C2 * (-0 + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 * y(N/2+3)
- y(N/2+4)) - B2 * (0- 8 * y(N/2+1) + 8 * y(N/2+3) - y(N/2+4)) - P *
KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2);

dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn *
y(N/4+2);

% Stage 3-PP --------Section 1
for I=3:PP
dydt(I) = C2 * (- y(I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)ys))))* Kag *(y(I))*(y(I));

dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 *
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I));

dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 *
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) +
Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn *
y(N/4+I);
end
% Stage (PP+1)-(PP+2) ---------Section2
U = Q2 / (AREA * E);
B1 = U / (2 * h);
Dl = 10 * U * 17e-4 * E;
C1 = Dl / (h ^ 2);
B2= U / (12 * h);
C2=Dl / (12 * h ^2);

% Stage (PP+1)-(PQ-2) ---------Section2

for I=PP+1:PQ-2
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
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* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)ys))))* Kag *(y(I))*(y(I));

dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 *
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I));

dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 *
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) +
Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn *
y(N/4+I);
end
% Stage (PQ-1)-(PQ) ---------Section2
dydt(PQ-1) = C2 * (- y(PQ-3) + 16 * y(PQ-2) - 30 * y(PQ-1) + 16 * y(PQ)
- y(PQ)) - B2 * (y(PQ-3) - 8 * y(PQ-2) + 8 * y(PQ) - y(PQ)) - P * KovI
* (KsecI * y(PQ-1) - y(N/4 +PQ-1)) - Krxn * y(PQ-1)-2 * (1/(1+exp(2*k*(y(PQ-1)-ys))))* Kag *(y(PQ-1))*(y(PQ-1));

dydt(N/4+PQ-1) = KovI *( KsecI * y(PQ-1)-y(N/4+PQ-1)) - Krxn *
y(N/4+PQ-1)-2 * (1/(1+exp(-2*k*(y(N/4+PQ-1)-ys))))* Kag *(y(N/4+PQ1))*(y(N/4+PQ-1));

dydt(N/2+PQ-1) = C2 * (- y(N/2+PQ-3) + 16 * y(N/2+PQ-2) - 30 *
y(N/2+PQ-1) + 16 * y(N/2+PQ) - y(N/2+PQ)) - B2 * (y(N/2+PQ-3) - 8 *
y(N/2+PQ-2) + 8 * y(N/2+PQ) - y(N/2+PQ)) - P * KovN * (KsecN *
y(N/2+PQ-1) - y(3*N/4+PQ-1)) + Krxn * y(PQ-1);

dydt(3*N/4+PQ-1) = KovN *( KsecN * y(N/2+PQ-1) -y(3*N/4+PQ-1)) + Krxn *
y(N/4+PQ-1);

dydt(PQ) = C1 * (y(PQ-1) -2 * y(PQ) + y(PQ)) - B1 * (- y(PQ-1) +
y(PQ)) - P * KovI * (KsecI * y(PQ) - y(N/4+PQ)) - Krxn * y(PQ)-2 *
(1/(1+exp(-2*k*(y(PQ)-ys))))* Kag *(y(PQ))*(y(PQ));

dydt(N/4+PQ) = KovI *( KsecI * y(PQ)-y(N/4+PQ)) - Krxn * y(N/4+PQ)-2 *
(1/(1+exp(-2*k*(y(N/4+PQ)-ys))))* Kag *(y(N/4+PQ))*(y(N/4+PQ));

106

dydt(N/2+PQ) = C1 * (y(N/2+PQ-1) - 2 * y(N/2+PQ) + y(N/2+PQ)) - B1 * (y(N/2+PQ-1) + y(N/2+PQ)) - P * KovN *(KsecN * y(N/2+PQ) - y(3*N/4+PQ))
+ Krxn * y(PQ);

dydt(3*N/4+PQ) = KovN *( KsecN * y(N/2+PQ) -y(3*N/4+PQ)) + Krxn *
y(N/4+PQ);

% Stage (PQ+1) AND (PQ+2)----------Feed point
U = Q3 / (AREA * E);
Dl = 10 * U * 17e-4 * E;
B1 = U / (2 * h);
C1 = Dl / (h ^ 2);
B2 = U / (12 * h);
C2 = Dl / (12 * h ^ 2);

dydt(PQ+1) = C1 * ((Q2 * y(PQ) / Q3 + QF * CfI/Q3) - 2 * y(PQ+1) +
y(PQ+2)) - B1 * (-(Q2 * y(PQ) / Q3 + QF * CfI / Q3) + y(PQ+2)) - P *
KovI * (KsecI * y(PQ+1) - y(N/4+PQ+1)) - Krxn * y(PQ+1)-2 * (1/(1+exp(2*k*(y(PQ+1)-ys))))* Kag *(y(PQ+1))*(y(PQ+1));

dydt(N/4+PQ+1) = KovI * ( KsecI * y(PQ+1) - y(N/4+PQ+1)) - Krxn *
y(N/4+PQ+1)-2 * (1/(1+exp(-2*k*(y(N/4+PQ+1)-ys))))* Kag
*(y(N/4+PQ+1))*(y(N/4+PQ+1));
dydt(N/2+PQ+1) = C1 * ((Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) - 2 *
y(N/2+PQ+1) + y(N/2+PQ+2)) - B1 * (-(Q2 * y(N/2+PQ) / Q3 + QF * CfN /
Q3) + y(N/2+PQ+2)) - P * KovN * (KsecN * y(N/2+PQ+1) - y(3*N/4+PQ+1)) +
Krxn * y(PQ+1);

dydt(3*N/4+PQ+1) = KovN *( KsecN * y(N/2+PQ+1) - y(3*N/4+PQ+1)) + Krxn
* y(N/4+PQ+1);

dydt(PQ+2) = C2 * ( -(Q2 * y(PQ) / Q3 + QF * CfI / Q3)+ 16 * y(PQ+1) 30 * y(PQ+2) + 16 * y(PQ+3) - y(PQ+4)) - B2 * ((Q2*y(PQ)/Q3+QF*CfI/Q3)
- 8 * y(PQ+1) + 8 * y(PQ+3) - y(PQ+4)) - P * KovI * (KsecI * y(PQ+2) y(N/4+PQ+2)) - Krxn * y(PQ+2)-2 * (1/(1+exp(-2*k*(y(PQ+2)-ys))))* Kag
*(y(PQ+2))*(y(PQ+2));

dydt(N/4+PQ+2) = KovI * ( KsecI * y(PQ+2) - y(N/4+PQ+2)) - Krxn *
y(N/4+PQ+2)-2 * (1/(1+exp(-2*k*(y(N/4+PQ+2)-ys))))* Kag
*(y(N/4+PQ+2))*(y(N/4+PQ+2));
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dydt(N/2+PQ+2) = C2 * (-(Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) + 16 *
y(N/2+PQ+1) - 30 * y(N/2+PQ+2) + 16 * y(N/2+PQ+3) - y(N/2+PQ+4)) - B2 *
((Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) - 8 * y(N/2+PQ+1) + 8 *
y(N/2+PQ+3) - y(N/2+PQ+4))- P * KovN * (KsecN * y(N/2+PQ+2) y(3*N/4+PQ+2)) + Krxn * y(PQ+2);

dydt(3*N/4+PQ+2) = KovN *( KsecN * y(N/2+PQ+2) - y(3*N/4+PQ+2)) + Krxn
* y(N/4+PQ+2);

% Stage (PQ+3)-(PQR) -------Section 3
for I=PQ+3:PQR
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)ys))))* Kag *(y(I))*(y(I));

dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 *
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I));

dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 *
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) +
Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn *
y(N/4+I);
end
% Stage (PQR+1)-N/4-2-------section 4
U = Q4 / (AREA * E);
Dl = 10 * U * 17e-4 * E;
B1 = U / (2 * h);
C1 = Dl / (h ^ 2);
B2 = U / (12 * h);
C2 = Dl / (12 * h ^ 2);
for I = PQR+1:N/4-2
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) y(I+2)) - B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)ys))))* Kag *(y(I))*(y(I));
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dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 *
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I));

dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 *
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) +
Krxn * y(I);

dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn *
y(N/4+I);
end
% last stage ----------Section 4
dydt(N/4-1) = C2 * (- y(N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 *
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4))
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1)-2*
(1/(1+exp(-2*k*(y(N/4-1)-ys))))* Kag *(y(N/4-1))*(y(N/4-1));

dydt(N/2-1) = KovI *( KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/2-1)-2
* (1/(1+exp(-2*k*(y(N/2-1)-ys))))* Kag *(y(N/2-1))*(y(N/2-1));

dydt(3*N/4-1) = C2 * (- y(3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1)
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 *
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn
* y(N/4-1);

dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1);

dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) + y(N/4)) - B1 * (- y(N/4-1) +
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4)- 2 *
(1/(1+exp(-2*k*(y(N/4)-ys))))* Kag *(y(N/4))*(y(N/4));

dydt(N/2) = KovI *( KsecI * y(N/4) - y(N/2)) - Krxn * y(N/2)-2 *
(1/(1+exp(-2*k*(y(N/2)-ys))))* Kag *(y(N/2))*(y(N/2));
dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn *
y(N/4);

dydt(N) = KovN *( KsecN * y(3*N/4) - y(N)) + Krxn * y(N/2);

109

Curriculum Vitae

Name:

PEGAH SAREMIRAD

Post-secondary
Education and
Degrees:

Western University
London, Ontario, Canada
2010-2015 Ph.D.
Western University
London, Ontario, Canada
2008-2010 M.E.Sc
Sharif University of Technology
Tehran, Iran
2001-2006 B.Sc

Honours and
Awards:

Province of Ontario Graduate Scholarship
2014-2015
Graduate Student Teaching Award (SOGS)
2014
Excellence in Teaching Award (Chemical Eng. Dept.)
2014

Related Work
Experience

Research Associate
Western University
2008-2015
Teaching Assistant
Western University
2008-2015

Publications and Conferences:
P. Saremirad, J.A. Wood, Y. Zhang, A.K. Ray, submitted to J. Chromatogr. A. 2015.
P. Saremirad, J.A. Wood, Y. Zhang, A.K. Ray, J. Chromatogr. A 2014, 1370, 145-155.
P. Saremirad, J.A. Wood, Y. Zhang, A.K. Ray, J. Chromatogr. A 2014, 1359, 70–75.
P. Saremirad, Y. Zhang, A.K. Ray, AIChE Annual Meeting, Nov 3-8, 2013, San
Francisco, CA , USA, Oral Presentation.
P. Saremirad, H.G. Gomaa, J. Zhu, J. Mem. Sci. 2012, 405-406, 158-166.

110

